## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

# **FORM 10-Q**

(Mark One)

☑ QUARTERLY RE	EPORT PURSUANT TO	SECTION 13 OR 15(d) OF	THE SECURITIES	S EXCHANGE A	ACT OF 1934
For the quarterly	period ended April 1	, 2023			
		or			
_		SECTION 13 OR 15(d) OF	THE SECURITIES	S EXCHANGE A	ACT OF 1934
For the transition	period from				
		Commission File Number:	000-06217		
		inte	8		
	IN	ITEL CORPO	RATION		
	(Exac	ct name of registrant as spe	cified in its charter)	)	
	<u>Delay</u>	<u>ware</u>		94	<u>-1672743</u>
(State	or other jurisdiction of i	ncorporation or organizatior	1)	(I.R.S. Employ	er Identification No.)
2200 Mission Coll		Santa Clara,	<u>California</u>		<u>054-1549</u>
	(Address of principa	al executive offices)		(Z	(ip Code)
	(Regis	(408) 765-8080 strant's telephone number, in		•)	
	(Former name, forme	N/A er address and former fiscal	year, if changed s	ince last report)	
Securities registered pur	suant to Section 12(b) o	f the Act:			
Title of each	class	Trading symbol(s)	Name of e	ach exchange o	on which registered
Common stock, \$0.0	001 par value	INTC	Na	isdaq Global Se	elect Market
Exchange Act of 1934 du	uring the preceding 12 m	) has filed all reports require nonths (or for such shorter p for the past 90 days. Yes $\  \  \  \  \  \  \  \  \  \  \  \  \ $	eriod that the regis		) of the Securities red to file such reports), and
	S-T (§232.405 of this cha	s submitted electronically e apter) during the preceding			to be submitted pursuant to lod that the registrant was
	g growth company. See	a large accelerated filer, an the definitions of "large acce f the Exchange Act.			
Large accelerated filer  ☑	Accelerated filer	Non-accelerated filer □	Smaller report		Emerging growth company
		ck mark if the registrant has ounting standards provided p			
Indicate by check mark w	whether the registrant is	a shell company (as defined	d in Rule 12b-2 of t	he Exchange A	ct). Yes □ No ☑
As of April 21, 2023, the	registrant had outstandi	ng 4,171 million shares of co	ommon stock.		

## **Table of Contents**

## Organization of Our Form 10-Q

The order and presentation of content in our Form 10-Q differs from the traditional SEC Form 10-Q format. Our format is designed to improve readability and better present how we organize and manage our business. See "Form 10-Q Cross-Reference Index" within Other Key Information for a cross-reference index to the traditional SEC Form 10-Q format.

We have defined certain terms and abbreviations used throughout our Form 10-Q in "Key Terms" within the Consolidated Condensed Financial Statements and Supplemental Details.

The preparation of our Consolidated Condensed Financial Statements is in conformity with US GAAP. Our Form 10-Q includes key metrics that we use to measure our business, some of which are non-GAAP measures. See "Non-GAAP Financial Measures" within MD&A for an explanation of these measures and why management uses them and believes they provide investors with useful supplemental information.

	Page
Forward-Looking Statements	1
Availability of Company Information	2
A Quarter in Review	3
Consolidated Condensed Financial Statements and Supplemental Details	
Consolidated Condensed Statements of Income	4
Consolidated Condensed Statements of Comprehensive Income	5
Consolidated Condensed Balance Sheets	6
Consolidated Condensed Statements of Cash Flows	7
Consolidated Condensed Statements of Stockholders' Equity	8
Notes to Consolidated Condensed Financial Statements	9
Key Terms	21
Management's Discussion and Analysis (MD&A)	
Segment Trends and Results	22
Consolidated Condensed Results of Operations	28
Liquidity and Capital Resources	33
Non-GAAP Financial Measures	34
Other Key Information	
Quantitative and Qualitative Disclosures About Market Risk	37
Risk Factors	37
Controls and Procedures	37
Issuer Purchases of Equity Securities	37
Disclosure Pursuant to Section 13(r) of the Securities Exchange Act of 1934	38
Exhibits	39
Form 10-Q Cross-Reference Index	40

## Forward-Looking Statements

This Form 10-Q contains forward-looking statements that involve a number of risks and uncertainties. Words such as "accelerate," "achieve," "aim," "ambitions," "anticipate," "believe," "committed," "continue," "could," "designed," "estimate," "expect," "forecast," "future," "goals," "grow," "guidance," "intend," "likely," "may," "might," "milestones," "next generation," "objective," "on track," "opportunity," "outlook," "pending," "plan," "position," "potential," "possible," "predict," "progress," "ramp," "roadmap," "seeks," "should," "strive," "targets," "to be," "upcoming," "will," "would," and variations of such words and similar expressions are intended to identify such forward-looking statements, which may include statements regarding:

- our business plans and strategy and anticipated benefits therefrom, including our IDM 2.0 strategy, our partnership with Brookfield, the transition to an internal foundry model, and updates to our reporting structure;
- · projections of our future financial performance, including future revenue, gross margins, capital expenditures, and cash flows;
- · projected costs and yield trends;
- future cash requirements and the availability, uses, sufficiency, and cost of capital resources, and sources of funding, including future
  capital and R&D investments, credit rating expectations, and expected returns to stockholders such as stock repurchases and
  dividends;
- future products, services and technologies, and the expected goals, timeline, ramps, progress, availability, production, regulation and benefits of such products, services and technologies, including future process nodes and packaging technology, product roadmaps, schedules, future product architectures, expectations regarding process performance, per-watt parity, and metrics and expectations regarding product and process leadership;
- investment plans, and impacts of investment plans, including in the US and abroad;
- internal and external manufacturing plans, including future internal manufacturing volumes, manufacturing expansion plans and the financing therefor, and external foundry usage;
- future production capacity and product supply;
- supply expectations, including regarding constraints, limitations, pricing, and industry shortages;
- plans and goals related to Intel's foundry business, including with respect to future manufacturing capacity and foundry service
  offerings, including technology and IP offerings;
- expected timing and impact of acquisitions, divestitures, and other significant transactions, including statements relating to the completion of our acquisition of Tower Semiconductor Ltd. and the sale of our NAND memory business;
- expected completion and impacts of restructuring activities and cost-saving or efficiency initiatives, including those related to the 2022 Restructuring Program;
- future social, and environmental performance, goals, measures and strategies;
- our anticipated growth, future market share, and trends in our businesses and operations;
- · projected growth and trends in markets relevant to our businesses;
- anticipated trends and impacts related to industry component, substrate, and foundry capacity utilization, shortages and constraints;
- expectations regarding government incentives;
- future technology trends;
- · future macro environmental and economic conditions, including regional or global downturns or recessions;
- future responses to and effects of COVID-19, including as to manufacturing, transportation and operational restrictions and disruptions and broader economic conditions;
- geopolitical conditions, including the impacts of Russia's war on Ukraine;
- tax- and accounting-related expectations;
- expectations regarding our relationships with certain sanctioned parties; and
- other characterizations of future events or circumstances.

Such statements involve many risks and uncertainties that could cause our actual results to differ materially from those expressed or implied, including:

- · changes in demand for our products;
- changes in product mix;
- · the complexity and fixed cost nature of our manufacturing operations;
- the high level of competition and rapid technological change in our industry;
- · the significant upfront investments in R&D and our business, products, technologies, and manufacturing capabilities;
- vulnerability to new product development and manufacturing-related risks, including product defects or errata, particularly as we develop next generation products and implement next generation process technologies;
- · risks associated with highly complex global supply chain, including from disruptions, delays, trade tensions, or shortages;
- sales-related risks, including customer concentration and the use of distributors and other third parties;
- potential security vulnerabilities in our products;

- · cybersecurity and privacy risks;
- investment and transaction risk;
- IP risks and risks associated with litigation and regulatory proceedings;
- evolving regulatory and legal requirements across many jurisdictions;
- geopolitical and international trade conditions;
- · our debt obligations;
- risks of large scale global operations;.
- · macroeconomic conditions;
- impacts of the COVID-19 or similar such pandemic;
- · other risks and uncertainties described in this report, our 2022 Form 10-K and our other filings with the SEC.

Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Readers are urged to carefully review and consider the various disclosures made in this Form 10-Q and in other documents we file from time to time with the SEC that disclose risks and uncertainties that may affect our business.

Unless specifically indicated otherwise, the forward-looking statements in this Form 10-Q do not reflect the potential impact of any divestitures, mergers, acquisitions, or other business combinations that have not been completed as of the date of this filing. In addition, the forward-looking statements in this Form 10-Q are based on management's expectations as of the date of this filing, unless an earlier date is specified, including expectations based on third-party information and projections that management believes to be reputable. We do not undertake, and expressly disclaim any duty, to update such statements, whether as a result of new information, new developments, or otherwise, except to the extent that disclosure may be required by law.

## **Availability of Company Information**


We use our Investor Relations website, <u>www.intc.com</u>, as a routine channel for distribution of important, and often material, information about us, including our quarterly and annual earnings results and presentations, press releases, announcements, information about upcoming webcasts, analyst presentations, and investor days, archives of these events, financial information, corporate governance practices, and corporate responsibility information. We do not distribute our financial results via a news wire service. All such information is available on our Investor Relations website free of charge. Our Investor Relations website allows interested persons to sign up to automatically receive e-mail alerts when we post financial information and issue press releases, and to receive information about upcoming events. We encourage interested persons to follow our Investor Relations website in addition to our filings with the SEC to timely receive information about the company.

Intel, the Intel logo, Intel Core, and Xeon are trademarks of Intel Corporation or its subsidiaries in the US and/or other countries.

\* Other names and brands may be claimed as the property of others.

## A Quarter in Review

Total revenue of \$11.7 billion was down \$6.6 billion or 36% from Q1 2022, as CCG revenue decreased 38%, DCAI revenue decreased 39%, and NEX revenue decreased 30%. Q1 2023 results were impacted by an uncertain macroeconomic environment, with slowing consumer and enterprise demand, persistent inflation, and higher interest rates, that we believe impacts our target markets and creates a high level of uncertainty with our customers. We believe CCG, DCAI, and NEX customers, among others, tempered purchases to reduce their existing inventories and adjust to the macroeconomic uncertainty. CCG revenue decreased due to lower notebook and desktop volumes on lower demand, while notebook ASPs decreased due to a higher mix of small core and older generation products. DCAI revenue decreased due to lower server volume resulting from a softening data center market, partially offset by an increase in revenue from the FPGA product line. NEX revenue decreased due to lower demand for Edge, Network Xeon, and Ethernet products.



## **Key Developments**

- CCG introduced the 13th Gen Intel® Core™ mobile processor family, led by the launch of the first 24-core processor for a laptop, and introduced the new Intel vPro® platform powered by the full lineup of 13th Gen Intel Core processors.
- DCAI launched the 4th Gen Intel® Xeon® Scalable processors, a critical part of our heterogeneous hardware and software portfolio to accelerate real-world workloads, including AI, and announced the 5th Gen Xeon Scalable processor.
- NEX launched the 4th Gen Intel<sup>®</sup> Xeon<sup>®</sup> Scalable processors with Intel<sup>®</sup> vRAN Boost, a new general-purpose chip that fully integrates
  Layer 1 acceleration into the Xeon SoC and is designed to eliminate the need for external accelerator cards.
- IFS announced a multigeneration agreement with Arm to enable chip designers to build low-power compute system-on-chips (SoCs) on the Intel 18A process.

intel A Quarter in Review 3

<sup>&</sup>lt;sup>1</sup> See "Non-GAAP Financial Measures" within MD&A.

# Consolidated Condensed Statements of Income

	Three Months Ended						
(In Millions, Except Per Share Amounts; Unaudited)	Apr 1, 2023	Apr 2, 2022					
Net revenue	\$ 11,715	\$ 18,353					
Cost of sales	7,707	9,109					
Gross margin	4,008	9,244					
Research and development	4,109	4,362					
Marketing, general, and administrative	1,303	1,752					
Restructuring and other charges	64	(1,211					
Operating expenses	5,476	4,903					
Operating income (loss)	(1,468)	4,341					
Gains (losses) on equity investments, net	169	4,323					
Interest and other, net	141	997					
Income (loss) before taxes	(1,158)	9,661					
Provision for taxes	1,610	1,548					
Net income (loss)	(2,768)	8,113					
Less: Net income (loss) attributable to non-controlling interests	(10)	_					
Net income (loss) attributable to Intel	\$ (2,758)	\$ 8,113					
Earnings (loss) per share attributable to Intel—basic	\$ (0.66)	\$ 1.99					
Earnings (loss) per share attributable to Intel—diluted	\$ (0.66)	\$ 1.98					
Weighted average shares of common stock outstanding:							
Basic	4,154	4,079					
Diluted	4,154	4,107					

# Consolidated Condensed Statements of Comprehensive Income

		Three Mon	ths En	ded
(In Millions; Unaudited)	Арі	r 1, 2023	Apr	2, 2022
Net income (loss)	\$	(2,768)	\$	8,113
Changes in other comprehensive income, net of tax:				
Net unrealized holding gains (losses) on derivatives		142		(115)
Actuarial valuation and other pension benefits (expenses), net		1		18
Translation adjustments and other				(25)
Other comprehensive income (loss)		143		(122)
Total comprehensive income (loss)		(2,625)		7,991
Less: comprehensive income (loss) attributable to non-controlling interests		(10)		_
Total comprehensive income (loss) attributable to Intel	\$	(2,615)	\$	7,991

# Consolidated Condensed Balance Sheets

(In Millions; Unaudited)		Apr 1, 2023		Dec 31, 2022		
Assets						
Current assets:						
Cash and cash equivalents	\$	8,232	\$	11,144		
Short-term investments		19,302		17,194		
Accounts receivable, net		3,847		4,133		
Inventories		12,993		13,224		
Other current assets		3,940		4,712		
Total current assets		48,314		50,407		
Property, plant and equipment, net of accumulated depreciation of \$94,550 (\$93,386 as of December 31, 2022)		85,734		80,860		
Equity investments		6,029		5,912		
Goodwill		27,591		27,591		
Identified intangible assets, net		5,567		6,018		
Other long-term assets		12,068		11,315		
Total assets	\$	185,303	\$	182,103		
Liabilities and stockholders' equity						
Current liabilities:						
Short-term debt	\$	1,437	\$	4,367		
Accounts payable		8,083		9,595		
Accrued compensation and benefits		2,497		4,084		
Income taxes payable		4,046		2,251		
Other accrued liabilities		11,330		11,858		
Total current liabilities		27,393		32,155		
Debt		48,836		37,684		
Long-term income taxes payable		3,831		3,796		
Other long-term liabilities		4,840		5,182		
Contingencies (Note 12)						
Stockholders' equity:						
Common stock and capital in excess of par value, 4,171 issued and outstanding (4,137 issued and outstanding as of December 31, 2022)		32,829		31,580		
Accumulated other comprehensive income (loss)		(419)		(562)		
Retained earnings		65,649		70,405		
Total Intel stockholders' equity		98,059		101,423		
Non-controlling interests		2,344		1,863		
Total stockholders' equity		100,403		103,286		
Total liabilities and stockholders' equity	\$	185,303	\$	182,103		

# Consolidated Condensed Statements of Cash Flows

Cash and cash equivalents, beginning of period			Three Mon	ths I	Ended
Cash flows provided by (used for) operating activities:         (2,768)         8,113           Net income (loss)         2,768         8,113           Adjustments to reconcile net income to net cash provided by operating activities:         1,901         2,847           Share-based compensation         1,901         2,847           Share-based compensation         55         1,7           Amortization of intangibles         465         501           (Gains) losses on dequity investments, net         (1,121)           (Gains) losses on divestitures         286         2,84           (Gains) losses and liabilities:         231         (1,147)           Accounts receivable         286         2,84           Inventories         231         (1,147)           Accounts payable         (1,560)         (1,884)           Accrued compensation and benefits         (1,560)         (1,884)           Income taxes         (1,560)         (1,884)           1 Cytal adjustments         (1,560)         (1,892)           Total adjustments         (1,560)         (1,892)           Net cash provided by (used for) investing activities:         (7,413)         (4,604)           Purchases of short-term investments         (1,612)         (1,991)	(In Millions; Unaudited)	Ар	r 1, 2023	A	or 2, 2022
Net income (loss)         2,768         8,113           Adjustments to reconcile net income to net cash provided by operating activities:         1,901         2,847           Share-based compensation         739         707           Restructuring and other charges         465         51           Amortization of intangibles         465         501           (Gains) losses on equity investments, net         (167)         (4,325)           (Gains) losses on divestitures         286         2,384           (Gains) losses on divestitures         231         (1,147)           Changes in assets and liabilities:         231         (1,147)           Accounts receivable         286         2,384           Inventories         231         (1,147)           Accounts payable         (771)         (128)           Accounts payable         (1,560)         (1,884)           Income taxes         1,344         (1,219)           Other assets and liabilities         (1,560)         (1,882)           Income taxes         1,344         (2,922)           Yet cash provided by (used for) operating activities         (7,413)         (4,604)           Protect cash provided by (used for) investing activities         (7,413)         (4,604)	Cash and cash equivalents, beginning of period	\$	11,144	\$	4,827
Adjustments to reconcile net income to net cash provided by operating activities:         1,901         2,847           Depreciation         739         707           Restructuring and other charges         55         17           Amortization of intangibles         65         501           (Gains) losses on equity investments, net         (167)         (4,325)           (Gains) losses on divestitures         286         2,384           Changes in assets and liabilities:         281         (1,147)           Accounts receivable         231         (1,147)           Accounts payable         271         (128)           Accounts payable         1,1560         (1,884)           Income taxes         1,1560         (1,812)           Total adjustments         (1,562)         (1,292)           Act as provided by (used for) investing activities         (1,512)         (1,512)	Cash flows provided by (used for) operating activities:				
Depreciation         1,901         2,847           Share-based compensation         707           Restructuring and other charges         55         177           Amortization of intangibles         465         501           (Gains) losses on quivity investments, net         (167         (4,325)           (Gains) losses on divestitures         — (1,121)           Changes in assets and liabilities:         — (2,121)           Accounts receivable         286         2,384           Inventories         231         (1,147)           Accoud compensation and benefits         (1,560)         (1,884)           Income taxes         1,344         1,219           Other assets and liabilities         (1,560)         (1,884)           Income taxes         1,344         1,219           Other assets and liabilities         (1,560)         (1,884)           Income taxes         1,344         1,219           Other assets and liabilities         (1,560)         (1,882)           Income taxes         (1,560)         (1,882)           Income taxes         (1,560)         (1,882)           Income taxes         (1,560)         (1,882)           Income taxes         (1,612)         (1,892)     <	Net income (loss)		(2,768)		8,113
Share-based compensation         739         707           Restructuring and other charges         55         17           Amortization of intangibles         465         501           (Gains) losses on equity investments, net         (167)         (4,325)           (Gains) losses on divestitures	Adjustments to reconcile net income to net cash provided by operating activities:				
Restructuring and other changes         55         17           Amortization of intangibles         465         501           (Calins) losses on equity investments, net         (167)         (4,325)           (Gains) losses and liabilities:         - (1,121)           Changes in assets and liabilities:         - 286         2,384           Inventories         231         (1,147)           Accounts payable         (1,560)         (1,884)           Accordompensation and benefits         (1,560)         (1,884)           Income taxes         (1,540)         (1,292)           Other assets and liabilities         (1,560)         (1,884)           Income taxes         (1,540)         (1,292)           Total adjustments         983         (2,222)           Nother assets and liabilities         (1,560)         (1,860)           Income taxes         (1,540)         (1,292)           Total adjustments         (1,560)         (1,292)           Total adjustments         (1,560)         (1,682)           Abditions provided by (used for) investing activities         (7,413)         (4,604)           Purchases of short-term investments         (16,132)         (19,091)           Maturities and sales of short-term investments	Depreciation		1,901		2,847
Amortization of intangibles         465         501           (Gains) losses on equity investments, net         (167)         (4,325)           (Gains) losses on equity investments, net         (1,121)           Changes in assets and liabilities:         286         2,384           Inventories         231         (1,147)           Accounts payable         (771)         (128)           Accound compensation and benefits         (1,560)         (1,884)           Income taxes         1,344         1,219           Other assets and liabilities         (1,560)         (1,884)           Income taxes         1,344         1,219           Other assets and liabilities         (1,560)         (1,889)           Net cash provided by (used for) operating activities         (1,560)         (1,289)           Net cash provided by (used for) investing activities         (7,413)         (4,604)           Purchases of short-term investments         (1,614)         (4,602)           Additions to property, plant and equipment         (7,413)         (4,602)           Purchases of short-term investments         (1,614)         (4,602)           Alturities and sales of short-term investments         (1,614)         (4,602)           Other investing         (2,634) <t< td=""><td>Share-based compensation</td><td></td><td>739</td><td></td><td>707</td></t<>	Share-based compensation		739		707
(Gains) losses on equity investments, net         (d.925)         (d.926)         (d.928)         (d.929)	Restructuring and other charges		55		17
(Gains) losses on divestitures         (1,121)           Changes in assets and liabilities:         2,384           Accounts receivable         231         (1,147)           Accounts payable         (771)         (128)           Accrued compensation and benefits         1,344         1,219           Income taxes         1,344         1,219           Other assets and liabilities         (1,540)         (1,292)           Total adjustments         983         2,222           Net cash provided by (used for) operating activities         983         2,222           Total adjustments         (1,540)         (1,292)           Net cash provided by (used for) investing activities         7,413         0,693           Cash flows provided by (used for) investing activities         (7,413)         0,604           Purchases of short-term investments         (16,132)         (19,091)           Maturities and sales of short-term investments         116         4,602           Sales of equity investments         116         4,602           Proceeds from divestitures         2,534         (2,639)           Other investing         2,534         (2,639)           Net cash used for investing activities         2,293         2,654           Other inve	Amortization of intangibles		465		501
Changes in assets and liabilities:         2,84           Accounts receivable         231         (1,147)           Accounts payable         (771)         (128)           Accounts payable         (1,560)         (1,884)           Income taxes         1,344         1,219           Other assets and liabilities         1,344         1,219           Other assets and liabilities         983         2,222           Net cash provided by (used for) operating activities         983         2,222           Net cash provided by (used for) investing activities         983         2,222           Net cash provided by (used for) investing activities         (7,413)         (4,604)           Purchases of short-term investments         (16,132)         (19,091)           Maturities and sales of short-term investments         116,132         (19,091)           Maturities and sales of short-term investments         116,142         (19,091)           Maturities and sales of short-term investments         116,142         (19,091)           Maturities and sales of short-term investments         116         4,682           Proceeds from divestitures         2,252         (660)           Net cash used for investing activities         2,253         (660)           Net cash used for inves	(Gains) losses on equity investments, net		(167)		(4,325)
Accounts receivable         236         2,384           Inventories         231         (1,147)           Accounts payable         (1771)         (1288)           Account compensation and benefits         (1,560)         (1,884)           Income taxes         1,344         2,129           Other assets and liabilities         (1,540)         (1,292)           Total adjustments         983         (2,222)           Net cash provided by (used for) operating activities         (1,785)         5,891           Cash flows provided by (used for) investing activities         (7,413)         (4,604)           Purchases of short-term investments         (16,132)         (19,091)           Maturities and sales of short-term investments         116,132         (19,091)           All contracting the stream investments         116,132         (2,654)           Other investing         (8,521)         (2,654) <td< td=""><td>(Gains) losses on divestitures</td><td></td><td>_</td><td></td><td>(1,121)</td></td<>	(Gains) losses on divestitures		_		(1,121)
Inventories	Changes in assets and liabilities:				
Accounts payable         (771)         (128)           Accrued compensation and benefits         (1,560)         (1,884)           Income taxes         1,344         1,219           Other assets and liabilities         (1,500)         (1,500)           Total adjustments         983         (2,222)           Net cash provided by (used for) operating activities         983         (2,222)           Cash flows provided by (used for) investing activities:         (7,413)         (4,604)           Purchases of short-term investments         (16,132)         (19,091)           Maturities and sales of short-term investments         (16,132)         (19,091)           Maturities and sales of short-term investments         116,322         (19,091)           Maturities and sales of short-term investments         116,322         (19,091)           Sales of equity investments         116,322         (19,091)           Meturities and sales of short-term investments         116,322         (19,091)           Sales of equity investments         116,322         (19,091)           Meturities and sales of short-term investments         116,522         (2,689)           Proceeds from divestitures         2,932         (2,689)           Cash laused for investing activities         2,933         1,932	Accounts receivable		286		2,384
Accrued compensation and benefits         (1,580)         (1,884)           Income taxes         1,344         1,219           Other assets and liabilities         (1,500)         (1,292)           Total adjustments         983         (2,222)           Net cash provided by (used for) operating activities         (1,785)         5,891           Cash flows provided by (used for) investing activities         (7,413)         (4,604)           Purchases of short-term investments         (16,132)         (19,091)           Maturities and sales of short-term investments         14,173         10,490           Sales of equity investments         116         4,682           Proceeds from divestitures         735         (660)           Other cash used for investing activities         (5,521)         (2,630)           Net cash used for investing activities         (8,521)         (2,630)           Payments of commercial paper         (2,930)         —           Payments on finance leases         (1,51)         (2,930)           Partner contributions         449         —           Issuance of long-term debt, net of issuance costs         10,968         —           Proceeds from sales of common stock through employee equity incentive plans         6,524         6,584	Inventories		231		(1,147)
Income taxes         1,344         1,219           Other assets and liabilities         (1,500)         (1,292)           Net cash provided by (used for) operating activities         983         (2,222)           Net cash provided by (used for) investing activities         (1,785)         5,891           Cash flows provided by (used for) investing activities         (7,413)         (4,604)           Purchases of short-term investments         (16,132)         (19,001)           Maturities and sales of short-term investments         14,173         10,490           Sales of equity investments         11,173         10,490           Sales of equity investments         11,173         10,490           Proceeds from divestitures         1         4,682           Proceeds from divestitures         8,521         660           Other investing         8,521         660           Net cash flows provided by (used for) financing activities         8,521         660           Repayment of commercial paper         2,930         -           Payments on finance leases         (15         (299)           Partner contributions         449         -           Issuance of long-term debt, net of issuance costs         10,968         -           Payment of dividends to stockhol	Accounts payable		(771)		(128)
Other assets and liabilities         (1,592)           Total adjustments         983         (2,222)           Net cash provided by (used for) operating activities         3,595           Cash flows provided by (used for) investing activities:         (7,413)         (4,604)           Additions to properly, plant and equipment         (7,413)         (4,604)           Purchases of short-term investments         (16,132)         (19,091)           Maturities and sales of short-term investments         116         4,682           Sales of equity investments         116         4,682           Proceeds from divestitures         116         4,682           Other investing         735         (660)           Net cash used for investing activities         8,521         (2,639)           Cash flows provided by (used for) financing activities         2,239         2           Repayments on finance leases         (2,930)         2           Payments on finance leases         (2,930)         2           Payment of commercial paper         (2,930)         2           Issuance of long-term debt, net of issuance costs         10,968         3           Payment of dividends to stockholders         15,122         (4,872)           Other financing         7,394         (	Accrued compensation and benefits		(1,560)		(1,884)
Total adjustments         983         (2,222)           Net cash provided by (used for) operating activities         (1,785)         5,891           Cash flows provided by (used for) investing activities:         (7,413)         (4,604)           Additions to property, plant and equipment         (16,132)         (19,091)           Muturities and sales of short-term investments         (16,132)         (19,091)           Maturities and sales of short-term investments         116         4,682           Proceeds from divestitures         116         4,682           Proceeds from divestitures         735         (660)           Other cash used for investing activities         (8,521)         (2,639)           Cash flows provided by (used for) financing activities         (2,930)         —           Repayment of commercial paper         (2,930)         —           Payments on finance leases         (2,930)         —           Payments on finance leases         (2,930)         —           Payment of commercial paper         (2,930)         —           Issuance of long-term debt, net of issuance costs         10,968         —           Proceeds from sales of common stock through employee equity incentive plans         659         589           Payment of dividends to stockholders         (2,25)	Income taxes		1,344		1,219
Net cash provided by (used for) operating activities         (1,785)         5,891           Cash flows provided by (used for) investing activities:         (7,413)         (4,604)           Additions to property, plant and equipment         (7,413)         (4,604)           Purchases of short-term investments         (16,132)         (19,091)           Maturities and sales of short-term investments         14,173         10,490           Sales of equity investments         116         4,682           Proceeds from divestitures         -         6,544           Other investing         (8,521)         (2,639)           Net cash used for investing activities         (8,521)         (2,639)           Cash flows provided by (used for) financing activities:         (2,930)         -           Repayment of commercial paper         (2,930)         -           Payments on finance leases         (15)         (299)           Partner contributions         449         -           Issuance of long-term debt, net of issuance costs         10,968         -           Proceeds from sales of common stock through employee equity incentive plans         (5,512)         (1,872)           Other financing         (2,52)         (667)           Net cash provided by (used for) financing activities         7,394 <td>Other assets and liabilities</td> <td></td> <td>(1,540)</td> <td></td> <td>(1,292)</td>	Other assets and liabilities		(1,540)		(1,292)
Cash flows provided by (used for) investing activities:         4 (4,604)           Additions to property, plant and equipment         (7,413)         (4,604)           Purchases of short-term investments         (16,132)         (19,091)           Maturities and sales of short-term investments         14,173         10,490           Sales of equity investments         116         4,682           Proceeds from divestitures         -         6,544           Other investing         735         (660)           Net cash used for investing activities         (8,521)         (2,639)           Cash flows provided by (used for) financing activities:         (8,521)         (2,639)           Cash flows provided by (used for) financing activities:         (8,521)         (2,639)           Cash flows provided by (used for) financing activities:         (8,521)         (2,639)           Payment of commercial paper         (2,930)         -           Payments on finance leases         (1,512)         (2,930)         -           Payments on finance leases         (1,512)         (2,940)         -           Payments on finance leases         (1,512)         (1,487)         -           Poceeds from sales of common stock through employee equity incentive plans         659         589           Pay	Total adjustments		983		(2,222)
Additions to property, plant and equipment         (7,413)         (4,604)           Purchases of short-term investments         (16,132)         (19,091)           Maturities and sales of short-term investments         14,173         10,490           Sales of equity investments         116         4,682           Proceeds from divestitures         -         6,544           Other investing         735         (660)           Net cash used for investing activities         (8,521)         (2,639)           Cash flows provided by (used for) financing activities:         (8,521)         (2,639)           Repayment of commercial paper         (2,930)         -           Payments on finance leases         (15)         (2990)           Partner contributions         449         -           Issuance of long-term debt, net of issuance costs         10,968         -           Proceeds from sales of common stock through employee equity incentive plans         659         589           Payment of dividends to stockholders         (1,512)         (1,487)           Other financing         (225)         (667)           Net cash provided by (used for) financing activities         7,394         (1,864)           Net increase (decrease) in cash and cash equivalents         2,912         1,388	Net cash provided by (used for) operating activities		(1,785)		5,891
Purchases of short-term investments         (16,132)         (19,091)           Maturities and sales of short-term investments         14,173         10,490           Sales of equity investments         116         4,682           Proceeds from divestitures         —         6,544           Other investing         735         (660)           Net cash used for investing activities         (8,521)         (2,639)           Cash flows provided by (used for) financing activities:         —         —           Repayment of commercial paper         (2,930)         —           Payments on finance leases         (15)         (2999)           Partner contributions         449         —           Issuance of long-term debt, net of issuance costs         10,968         —           Proceeds from sales of common stock through employee equity incentive plans         659         589           Payment of dividends to stockholders         (1,512)         (1,487)           Other financing         (225)         (667)           Net cash provided by (used for) financing activities         7,394         (1,864)           Net cash provided by (used for) financing activities         (2,912)         1,388           Cash and cash equivalents, end of period         8,232         6,215 <tr< td=""><td>Cash flows provided by (used for) investing activities:</td><td></td><td></td><td></td><td></td></tr<>	Cash flows provided by (used for) investing activities:				
Maturities and sales of short-term investments         14,173         10,490           Sales of equity investments         116         4,682           Proceeds from divestitures         —         6,544           Other investing         735         (660)           Net cash used for investing activities         (8,521)         (2,639)           Cash flows provided by (used for) financing activities:         —           Repayment of commercial paper         (2,930)         —           Payments on finance leases         (15)         (299)           Partner contributions         449         —           Issuance of long-term debt, net of issuance costs         10,968         —           Proceeds from sales of common stock through employee equity incentive plans         659         589           Payment of dividends to stockholders         (1,512)         (1,487)           Other financing         (225)         (667)           Net cash provided by (used for) financing activities         7,394         (1,864)           Net cash provided by (used for) financing activities         2,912         1,388           Cash and cash equivalents, end of period         8,322         6,215           Supplemental disclosures:         4,711         2,949           Acquisition of property,	Additions to property, plant and equipment		(7,413)		(4,604)
Sales of equity investments         116         4,682           Proceeds from divestitures         6,544         6,544           Other investing         735         (660)           Net cash used for investing activities         (8,521)         (2,639)           Cash flows provided by (used for) financing activities:         (2,930)         —           Repayment of commercial paper         (2,930)         —           Payments on finance leases         (15)         (299)           Partner contributions         449         —           Issuance of long-term debt, net of issuance costs         10,968         —           Proceeds from sales of common stock through employee equity incentive plans         659         589           Payment of dividends to stockholders         (1,512)         (1,487)           Other financing         (225)         (667)           Net cash provided by (used for) financing activities         7,394         (1,864)           Net increase (decrease) in cash and cash equivalents         (2,912)         1,388           Cash and cash equivalents, end of period         \$8,232         \$6,215           Supplemental disclosures:         4,711         \$2,949           Cash paid during the period for:         1,712         1,712         1,712	Purchases of short-term investments		(16,132)		(19,091)
Proceeds from divestitures         —         6,544           Other investing         735         (660)           Net cash used for investing activities         (8,521)         (2,639)           Cash flows provided by (used for) financing activities:         —           Repayment of commercial paper         (2,930)         —           Payments on finance leases         (15)         (299)           Partner contributions         449         —           Issuance of long-term debt, net of issuance costs         10,968         —           Proceeds from sales of common stock through employee equity incentive plans         659         589           Payment of dividends to stockholders         (1,512)         (1,487)           Other financing         (225)         (667)           Net cash provided by (used for) financing activities         7,394         (1,864)           Net increase (decrease) in cash and cash equivalents         (2,912)         1,388           Cash and cash equivalents, end of period         \$ 8,232         \$ 6,215           Supplemental disclosures:           Acquisition of property, plant and equipment included in accounts payable and accrued liabilities         4,711         \$ 2,949           Cash paid during the period for:         Interest, net of capitalized interest         313	Maturities and sales of short-term investments		14,173		10,490
Other investing         735         (660)           Net cash used for investing activities         (8,521)         (2,639)           Cash flows provided by (used for) financing activities:         (2,930)         —           Repayment of commercial paper         (2,930)         —           Payments on finance leases         (15)         (299)           Partner contributions         449         —           Issuance of long-term debt, net of issuance costs         10,968         —           Proceeds from sales of common stock through employee equity incentive plans         659         589           Payment of dividends to stockholders         (1,512)         (1,487)           Other financing         (225)         (667)           Net cash provided by (used for) financing activities         7,394         (1,864)           Net increase (decrease) in cash and cash equivalents         (2,912)         1,388           Cash and cash equivalents, end of period         \$2,212         1,388           Cash paid during the period for:         4,711         \$2,949           Cash paid during the period for:         1,771         \$313         \$177	Sales of equity investments		116		4,682
Net cash used for investing activities         (8,521)         (2,639)           Cash flows provided by (used for) financing activities:         (2,930)         —           Repayment of commercial paper         (2,930)         —           Payments on finance leases         (15)         (299)           Partner contributions         449         —           Issuance of long-term debt, net of issuance costs         10,968         —           Proceeds from sales of common stock through employee equity incentive plans         659         589           Payment of dividends to stockholders         (1,512)         (1,487)           Other financing         (225)         (667)           Net cash provided by (used for) financing activities         7,394         (1,864)           Net increase (decrease) in cash and cash equivalents         (2,912)         1,388           Cash and cash equivalents, end of period         \$ 8,232         6,215           Supplemental disclosures:         Acquisition of property, plant and equipment included in accounts payable and accrued liabilities         4,711         \$ 2,949           Cash paid during the period for:         Interest, net of capitalized interest         \$ 313         177	Proceeds from divestitures		_		6,544
Cash flows provided by (used for) financing activities:  Repayment of commercial paper  Payments on finance leases  (15) (299)  Partner contributions  Issuance of long-term debt, net of issuance costs  Proceeds from sales of common stock through employee equity incentive plans  Payment of dividends to stockholders  Other financing  (225) (667)  Net cash provided by (used for) financing activities  Net increase (decrease) in cash and cash equivalents  Cash and cash equivalents, end of period  Supplemental disclosures:  Acquisition of property, plant and equipment included in accounts payable and accrued liabilities  (2,930)  (299)  (299)  (1,949)  (1,968)  (1,512) (1,487) (1,487) (1,864)  (1,512) (1,487) (1,864)  (1,864)  (2,912) (1,388) (2,912) (1,388) (2,912) (1,388) (2,912) (1,388) (2,912) (1,388) (2,912) (1,388) (2,912) (1,388) (2,912) (1,388) (2,912) (1,388) (2,912) (1,388) (2,912) (1,388) (2,912) (1,388) (2,912) (1,388) (2,912) (1,388) (1,	Other investing				(660)
Repayment of commercial paper         (2,930)         —           Payments on finance leases         (15)         (299)           Partner contributions         449         —           Issuance of long-term debt, net of issuance costs         10,968         —           Proceeds from sales of common stock through employee equity incentive plans         659         589           Payment of dividends to stockholders         (1,512)         (1,487)           Other financing         (225)         (667)           Net cash provided by (used for) financing activities         7,394         (1,864)           Net increase (decrease) in cash and cash equivalents         (2,912)         1,388           Cash and cash equivalents, end of period         \$8,232         \$6,215           Supplemental disclosures:         Acquisition of property, plant and equipment included in accounts payable and accrued liabilities         4,711         \$2,949           Cash paid during the period for:         Interest, net of capitalized interest         \$313         \$177	Net cash used for investing activities		(8,521)		(2,639)
Payments on finance leases  Partner contributions  Issuance of long-term debt, net of issuance costs  Proceeds from sales of common stock through employee equity incentive plans  Payment of dividends to stockholders  Other financing  Net cash provided by (used for) financing activities  Net increase (decrease) in cash and cash equivalents  Cash and cash equivalents, end of period  Supplemental disclosures:  Acquisition of property, plant and equipment included in accounts payable and accrued liabilities  Acquisition of capitalized interest  Interest, net of capitalized interest  (15)  (299)  (449)  (1,968)  (1,512)  (1,487)  (225)  (667)  (4,864)  (2,912)  1,388  2,949  (3,711)  2,949	Cash flows provided by (used for) financing activities:				
Partner contributions 449 — Issuance of long-term debt, net of issuance costs 10,968 — Proceeds from sales of common stock through employee equity incentive plans 659 589 Payment of dividends to stockholders (1,512) (1,487) Other financing (225) (667) Net cash provided by (used for) financing activities 7,394 (1,864) Net increase (decrease) in cash and cash equivalents (2,912) 1,388 Cash and cash equivalents, end of period \$8,232 \$6,215  Supplemental disclosures: Acquisition of property, plant and equipment included in accounts payable and accrued liabilities \$4,711 \$2,949 Cash paid during the period for: Interest, net of capitalized interest \$313 \$177	Repayment of commercial paper		(2,930)		_
Issuance of long-term debt, net of issuance costs  Proceeds from sales of common stock through employee equity incentive plans  Payment of dividends to stockholders  Other financing  Net cash provided by (used for) financing activities  Net increase (decrease) in cash and cash equivalents  Cash and cash equivalents, end of period  Supplemental disclosures:  Acquisition of property, plant and equipment included in accounts payable and accrued liabilities  Acquisition of capitalized interest  10,968   10,968   10,968  589  (1,512)  (1,487)  (1,864)  7,394  (1,864)  8,232  \$ 6,215  1,388  4,711  \$ 2,949  Cash paid during the period for:  Interest, net of capitalized interest	Payments on finance leases				(299)
Proceeds from sales of common stock through employee equity incentive plans  Payment of dividends to stockholders  Other financing  Net cash provided by (used for) financing activities  Net increase (decrease) in cash and cash equivalents  Cash and cash equivalents, end of period  Supplemental disclosures:  Acquisition of property, plant and equipment included in accounts payable and accrued liabilities  Acquisition of capitalized interest  \$ 313 \$ 177	Partner contributions				_
Payment of dividends to stockholders  Other financing  Net cash provided by (used for) financing activities  Net increase (decrease) in cash and cash equivalents  Cash and cash equivalents, end of period  Supplemental disclosures:  Acquisition of property, plant and equipment included in accounts payable and accrued liabilities  Acquisition of capitalized interest  (1,512)  (1,487)  (225)  (1,864)  (1,864)  (2,912)  1,388  5,215  4,711  2,949	Issuance of long-term debt, net of issuance costs				_
Other financing  Net cash provided by (used for) financing activities  Net increase (decrease) in cash and cash equivalents  Cash and cash equivalents, end of period  Supplemental disclosures:  Acquisition of property, plant and equipment included in accounts payable and accrued liabilities  Acquisition of capitalized interest	Proceeds from sales of common stock through employee equity incentive plans				
Net cash provided by (used for) financing activities  Net increase (decrease) in cash and cash equivalents  Cash and cash equivalents, end of period  Supplemental disclosures:  Acquisition of property, plant and equipment included in accounts payable and accrued liabilities  Acquisition of capitalized interest	Payment of dividends to stockholders				
Net increase (decrease) in cash and cash equivalents  Cash and cash equivalents, end of period  Supplemental disclosures:  Acquisition of property, plant and equipment included in accounts payable and accrued liabilities  Cash paid during the period for:  Interest, net of capitalized interest  1,388  8,232  4,711  2,949  313  177	Other financing				
Cash and cash equivalents, end of period \$8,232 \$6,215  Supplemental disclosures:  Acquisition of property, plant and equipment included in accounts payable and accrued liabilities \$4,711 \$2,949  Cash paid during the period for:  Interest, net of capitalized interest \$313 \$177					
Supplemental disclosures:  Acquisition of property, plant and equipment included in accounts payable and accrued liabilities \$ 4,711 \$ 2,949  Cash paid during the period for:  Interest, net of capitalized interest \$ 313 \$ 177					
Acquisition of property, plant and equipment included in accounts payable and accrued liabilities \$ 4,711 \$ 2,949  Cash paid during the period for:  Interest, net of capitalized interest \$ 313 \$ 177	Cash and cash equivalents, end of period	\$	8,232	\$	6,215
Cash paid during the period for: Interest, net of capitalized interest \$ 313 \$ 177	Supplemental disclosures:				
Interest, net of capitalized interest \$ 313 \$ 177		\$	4,711	\$	2,949
	Cash paid during the period for:				
Income taxes, net of refunds \$ 267 \$ 335	·				
,	Income taxes, net of refunds	\$	267	\$	335

# Consolidated Condensed Statements of Stockholders' Equity

	Common Stock and Capital in Excess of Par Value		Accumulated Other		Non-						
(In Millions, Except Per Share Amounts; Unaudited)	5	Shares	Amount		mprehensive come (Loss)		etained arnings		ntrolling terests		Total
Three Months Ended											
Balance as of December 31, 2022	\$	4,137	\$ 31,580	\$	(562)	\$	70,405	\$	1,863	\$	103,286
Net income (loss)		_	_		_		(2,758)		(10)		(2,768)
Other comprehensive income (loss)		_	_		143		_		_		143
Net proceeds received from partner contributions		_	_		_		_		449		449
Employee equity incentive plans and other		36	659		_						659
Share-based compensation		_	697		_		_		42		739
Restricted stock unit withholdings		(2)	(107)		_		38		_		(69)
Cash dividends declared (\$0.49 per share)		_	_		_		(2,036)		_		(2,036)
Balance as of April 1, 2023	\$	4,171	\$ 32,829	\$	(419)	\$	65,649	\$	2,344	\$	100,403
Balance as of December 25, 2021	\$	4,070	\$ 28,006	\$	(880)	\$	68,265	\$	_	\$	95,391
Net income (loss)		_	_		_		8,113		_		8,113
Other comprehensive income (loss)		_	_		(122)		_		_		(122)
Employee equity incentive plans and other		20	589		_		_		_		589
Share-based compensation		_	707		_		_				707
Restricted stock unit withholdings		(1)	(58)		_		3		_		(55)
Cash dividends declared (\$0.37 per share)							(1,487)				(1,487)
Balance as of April 2, 2022	\$	4,089	\$ 29,244	\$	(1,002)	\$	74,894	\$		\$	103,136

# Notes to Consolidated Condensed Financial Statements

## Note 1: Basis of Presentation

We prepared our interim Consolidated Condensed Financial Statements that accompany these notes in conformity with US GAAP, consistent in all material respects with those applied in our 2022 Form 10-K.

We have a 52- or 53-week fiscal year that ends on the last Saturday in December. Fiscal year 2023 is a 52-week fiscal year; fiscal 2022 was a 53-week fiscal year, with the extra week included in the first guarter of 2022.

We have made estimates and judgments affecting the amounts reported in our Consolidated Condensed Financial Statements and the accompanying notes. The actual results that we experience may differ materially from our estimates. The interim financial information is unaudited, and reflects all normal adjustments that are, in our opinion, necessary to provide a fair statement of results for the interim periods presented. This report should be read in conjunction with the Consolidated Financial Statements in our 2022 Form 10-K where we include additional information on our critical accounting estimates, policies, and the methods and assumptions used in our estimates.

## Note 2: Operating Segments

We previously announced the organizational change to integrate AXG into CCG and DCAI. This change is intended to drive a more effective go-to-market capability and to accelerate the scale of these businesses, while also reducing costs. As a result, we modified our segment reporting in the first quarter of 2023 to align to this and certain other business reorganizations. All prior-period segment data has been retrospectively adjusted to reflect the way our CODM internally receives information and manages and monitors our operating segment performance starting in fiscal year 2023.

We now manage our business through the following operating segments:

- Client Computing (CCG)
- Data Center and AI (DCAI)
- Network and Edge (NEX)
- Mobileye

intel

Intel Foundry Services (IFS)

We derive a substantial majority of our revenue from our principal products that incorporate various components and technologies, including a microprocessor and chipset, a stand-alone SoC, or a multichip package, which is based on Intel<sup>®</sup> architecture.

CCG, DCAI and NEX are our reportable operating segments. Mobileye and IFS do not qualify as reportable operating segments; however, we have elected to disclose the results of these non-reportable operating segments. When we enter into federal contracts, they are aligned to the sponsoring operating segment.

We have sales and marketing, manufacturing, engineering, finance, and administration groups. Expenses for these groups are generally allocated to the operating segments.

We have an "all other" category that includes revenue, expenses, and charges such as:

- results of operations from non-reportable segments not otherwise presented, and from start-up businesses that support our initiatives;
- historical results of operations from divested businesses;
- amounts included within restructuring and other charges;
- employee benefits, compensation, impairment charges, and other expenses not allocated to the operating segments; and
- acquisition-related costs, including amortization and any impairment of acquisition-related intangibles and goodwill.

The CODM, who is our CEO, allocates resources to and assesses the performance of each operating segment using information about the operating segment's revenue and operating income (loss). The CODM does not evaluate operating segments using discrete asset information, and we do not identify or allocate assets by operating segments. Based on the interchangeable nature of our manufacturing and assembly and test assets, most of the related depreciation expense is not directly identifiable within our operating segments, as it is included in overhead cost pools and subsequently absorbed into inventory as each product passes through our manufacturing process. Because our products are then sold across multiple operating segments, it is impracticable to determine the total depreciation expense included as a component of each operating segment's operating income (loss) results. We do not allocate gains and losses from equity investments, interest and other income, share-based compensation, or taxes to our operating segments. Although the CODM uses operating income (loss) to evaluate the segments, operating costs included in one segment may benefit other segments. The accounting policies for segment reporting are the same as for Intel as a whole. There have been no changes to our segment accounting policies disclosed in our 2022 Form 10-K except for the organizational change described above.

Three Months Ended

Net revenue and operating income (loss) for each period were as follows:

	Three Months Ended						
(In Millions)	Apr 1, 2023	Apr 2, 2022					
Net revenue:							
Client Computing							
Desktop	\$ 1,879	\$ 2,641					
Notebook	3,407	5,959					
Other	483	722					
	5,767	9,322					
Data Center and Al	3,718	6,074					
Network and Edge	1,489	2,139					
Mobileye	458	394					
Intel Foundry Services	118	156					
All other	165	268					
Total net revenue	\$ 11,715	\$ 18,353					
Operating income (loss):							
Client Computing	\$ 520	\$ 2,722					
Data Center and Al	(518	1,393					
Network and Edge	(300	) 416					
Mobileye	123	148					
Intel Foundry Services	(140	(23)					
All other	(1,153	(315)					
Total operating income (loss)	\$ (1,468	\$ 4,341					

## Note 3: Non-Controlling Interests

## Semiconductor Co-Investment Program

In 2022, we closed a transaction with Brookfield Asset Management (Brookfield) resulting in the formation of Arizona Fab LLC (Arizona Fab), a VIE for which we and Brookfield own 51% and 49%, respectively. Because we are the primary beneficiary of the VIE, we fully consolidate the results of Arizona Fab into our consolidated financial statements. Generally, contributions will be made to, and distributions will be received from, Arizona Fab based on both parties' proportional ownership. We will be the sole operator and majority owner of two new chip factories that will be constructed by Arizona Fab, and we will have the right to purchase 100% of the related factory output. Once production commences, we will be required to operate Arizona Fab at minimum production levels measured in wafer starts per week and will be required to limit excess inventory held on site or we will be subject to certain penalties.

We have an unrecognized commitment to fund our respective share of the total construction costs of Arizona Fab of \$29.0 billion.

As of April 1, 2023, a substantial majority of the assets of Arizona Fab consisted of property, plant and equipment. The assets held by Arizona Fab, which can be used only to settle obligations of the VIE and are not available to us, were \$2.7 billion as of April 1, 2023 (\$1.8 billion as of December 31, 2022).

Non-controlling interest in Arizona Fab was \$1.3 billion as of April 1, 2023 (\$874 million as of December 31, 2022). Net loss attributable to non-controlling interest in Arizona Fab was \$5 million in the first three months of 2023; there was no net income (loss) attributable to non-controlling interest in the first three months of 2022.

#### Mobileye

In October 2022, Mobileye completed its IPO and certain other equity financing transactions that resulted in net proceeds of \$1.0 billion. As of April 1, 2023, Intel held approximately 94% (94% as of December 31, 2022) of the outstanding equity interest in Mobileye. Non-controlling interest in Mobileye was \$1.0 billion as of April 1, 2023 (\$1.0 billion as of December 31, 2022). Net loss attributable to non-controlling interest in Mobileye was \$5 million in the first three months of 2023; there was no net income (loss) attributable to non-controlling interest in the first three months of 2022.

# Note 4: Earnings (Loss) Per Share

We computed basic earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding during the period. We computed diluted earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding plus potentially dilutive shares of common stock outstanding the period.

Less: Net income (loss) attributable to non-controlling interests  Net income (loss) attributable to Intel  Weighted average shares of common stock outstanding—basic  Dilutive effect of employee equity incentive plans  Weighted average shares of common stock outstanding—diluted  4,154  4,100		T	ns Ended	
Less: Net income (loss) attributable to non-controlling interests  Net income (loss) attributable to Intel  Weighted average shares of common stock outstanding—basic  Dilutive effect of employee equity incentive plans  Weighted average shares of common stock outstanding—diluted  (2,758)  4,154  4,07  Dilutive effect of employee equity incentive plans  Weighted average shares of common stock outstanding—diluted  4,154  4,10	(In Millions, Except Per Share Amounts)	Apr 1,	2023	Apr 2, 2022
Net income (loss) attributable to Intel(2,758)8,11Weighted average shares of common stock outstanding—basic4,1544,07Dilutive effect of employee equity incentive plans—2Weighted average shares of common stock outstanding—diluted4,1544,10	Net income (loss)	\$	(2,768)	8,113
Weighted average shares of common stock outstanding—basic       4,154       4,07         Dilutive effect of employee equity incentive plans       —       2         Weighted average shares of common stock outstanding—diluted       4,154       4,100	Less: Net income (loss) attributable to non-controlling interests		(10)	_
Dilutive effect of employee equity incentive plans  Weighted average shares of common stock outstanding—diluted  4,154  4,100	Net income (loss) attributable to Intel		(2,758)	8,113
Weighted average shares of common stock outstanding—diluted 4,154 4,10	Weighted average shares of common stock outstanding—basic		4,154	4,079
	Dilutive effect of employee equity incentive plans		_	28
Earnings (loss) per share attributable to Intel—basic \$ (0.66) \$ 1.9	Weighted average shares of common stock outstanding—diluted		4,154	4,107
	Earnings (loss) per share attributable to Intel—basic	\$	(0.66)	1.99
Earnings (loss) per share attributable to Intel—diluted \$\(0.66\) \$\(1.9\)	Earnings (loss) per share attributable to Intel—diluted	\$	(0.66)	1.98

Potentially dilutive shares of common stock from employee equity incentive plans are determined by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan. Due to our net loss in the first three months of 2023, the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan had an antidilutive effect on diluted earnings per share.

Securities which were anti-dilutive were insignificant and were excluded from the computation of diluted earnings per share in all periods presented.

## Note 5: Other Financial Statement Details

#### Accounts Receivable

We sell certain of our accounts receivable on a non-recourse basis to third-party financial institutions. We record these transactions as sales of receivables and present cash proceeds as *cash provided by operating activities* in the Consolidated Condensed Statements of Cash Flows. Accounts receivable sold under non-recourse factoring arrangements were \$500 million during the first three months of 2023, and we did not factor accounts receivable during the first three months of 2022. After the sale of our accounts receivable, we will collect payment from the customers and remit it to the third-party financial institution.

#### Inventories

(In Millions)	Ар	r 1, 2023	Dec	31, 2022
Raw materials	\$	1,358	\$	1,517
Work in process		7,415		7,565
Finished goods		4,220		4,142
Total inventories	\$	12,993	\$	13,224

## Interest and Other, Net

	Three Months Ended							
(In Millions)	Apr	1, 2023	Apr 2, 2022					
Interest income	\$	334	\$	47				
Interest expense		(193)		(124)				
Other, net		_		1,074				
Total interest and other, net	\$	141	\$	997				

Interest expense is net of \$363 million of interest capitalized in the first three months of 2023 (\$142 million in the first three months of 2022). Other, net includes a gain in 2022 of \$1.0 billion resulting from the first closing of the divestiture of our NAND memory business.

## Property, Plant and Equipment

Effective January 2023, we increased the estimated useful life of certain production machinery and equipment from 5 years to 8 years. We estimate this change resulted in an approximate \$360 million increase to gross margin, an approximate \$100 million decrease in R&D expenses, and an approximate \$525 million decrease in ending inventory values in Q1 2023 when compared to what the impact would have been using the estimated useful life in place prior to this change.

## Note 6: Restructuring and Other Charges

	T	Three Months En				
(In Millions)	Apr	Apr 1, 2023		Apr 1, 2023		2, 2022
Employee severance and benefit arrangements	\$	(39)	\$	5		
Litigation charges and other		77		(1,216)		
Asset impairment charges		26		_		
Total restructuring and other charges	\$	64	\$	(1,211)		

The 2022 Restructuring Program was approved in the third quarter of 2022 to rebalance our workforce and operations to create efficiencies and improve our product execution in alignment with our strategy. We expect these actions to be substantially completed by the end of 2023, but this is subject to change. Any changes to the estimates or timing of executing the 2022 Restructuring Program will be reflected in our results of operations.

Restructuring activity for the 2022 Restructuring Program during the first three months of 2023 was as follows:

#### (In Millions)

Accrued restructuring balance as of December 31, 2022	\$ 873
Adjustments	(41)
Cash payments	 (487)
Accrued restructuring balance as of April 1, 2023	\$ 345

The accrued restructuring balance as of April 1, 2023, was recorded as a current liability within accrued compensation and benefits on the Consolidated Condensed Balance Sheets.

Litigation charges and other includes a \$1.2 billion benefit in the first three months of 2022 from the annulled penalty related to an EC fine that was recorded and paid in 2009. Refer to "Note 12: Contingencies" within the Notes to Consolidated Condensed Financial Statements for further information on legal proceedings related to the EC fine.

## Note 7: Investments

#### Short-term Investments

Short-term investments include marketable debt investments in corporate debt, government debt, and financial institution instruments. Government debt includes instruments such as non-US government bonds and US agency securities. Financial institution instruments include instruments issued or managed by financial institutions in various forms, such as commercial paper, fixed- and floating-rate bonds, money market fund deposits, and time deposits. As of April 1, 2023, and December 31, 2022, substantially all time deposits were issued by institutions outside the US.

For certain of our marketable debt investments, we economically hedge market risks at inception with a related derivative instrument or the marketable debt investment itself is used to economically hedge currency exchange rate risk from remeasurement. These hedged investments are reported at fair value with gains or losses from the investments and the related derivative instruments recorded in *interest and other, net*. The fair value of our hedged investments was \$18.2 billion as of April 1, 2023 (\$16.2 billion as of December 31, 2022). For hedged investments still held at the reporting date, we recorded net gains of \$90 million in the first three months of 2023 (\$411 million of net losses in the first three months of 2022). We recorded net losses on the related derivatives of \$102 million in the first three months of 2023 (\$377 million of net gains in the first three months of 2022).

Our remaining unhedged marketable debt investments are reported at fair value, with unrealized gains or losses, net of tax, recorded in accumulated other comprehensive income (loss). The adjusted cost of our unhedged investments was \$7.0 billion as of April 1, 2023 (\$10.2 billion as of December 31, 2022), which approximated the fair value for these periods.

The fair value of marketable debt investments, by contractual maturity, as of April 1, 2023, was as follows:

(In Millions)			
Due in 1 year or less	\$	15,874	
Due in 1–2 years		1,805	
Due in 2–5 years		4,850	
Due after 5 years		734	
Instruments not due at a single maturity date <sup>1</sup>		1,947	
Total	\$	25,210	

Instruments not due at a single maturity date is comprised of money market fund deposits, which are classified as either short-term investments or cash and cash equivalents.

## **Equity Investments**

(In Millions)	Apr 1, 2023		Dec 3	1, 2022
Marketable equity securities <sup>1</sup>	\$	1,421	\$	1,341
Non-marketable equity securities		4,598		4,561
Equity method investments		10		10
Total	\$	6,029	\$	5,912

<sup>&</sup>lt;sup>1</sup> Over 90% of our marketable equity securities are subject to trading-volume or market-based restrictions, which limit the number of shares we may sell in a specified period of time, impacting our ability to liquidate these investments. The trading volume restrictions generally apply for as long as we own more than 1% of the outstanding shares. Market-based restrictions result from the rules of the respective exchange.

The components of gains (losses) on equity investments, net for each period were as follows:

	Three Months Ended						
(In Millions)	Apr	1, 2023	Apr	2, 2022			
Ongoing mark-to-market adjustments on marketable equity securities	\$	188	\$	(430)			
Observable price adjustments on non-marketable equity securities		10		71			
Impairment charges		(36)		(23)			
Sale of equity investments and other <sup>1</sup>		7		4,705			
Total gains (losses) on equity investments, net	\$	169	\$	4,323			

Sale of equity investments and other includes initial fair value adjustments recorded upon a security becoming marketable, realized gains (losses) on sales of non-marketable equity investments and equity method investments, and our share of equity method investee gains (losses) and distributions.

Net unrealized gains and losses for our marketable and non-marketable equity securities for each period were as follows:

	Three Months Ended						
(In Millions)		1, 2023	Apr 2, 2022				
Net unrealized gains (losses) recognized during the period on equity securities	\$	166	\$	(244)			
Less: Net (gains) losses recognized during the period on equity securities sold during the period		(3)		(17)			
Net unrealized gains (losses) recognized during the reporting period on equity securities still held at the reporting date	\$	163	\$	(261)			

## McAfee Corp.

During the first quarter of 2022, the sale of the McAfee consumer business was completed and we received \$4.6 billion in cash for the sale of our remaining share of McAfee, recognizing a \$4.6 billion gain in sale of equity investments and other.

## Note 8: Acquisitions and Divestitures

## Acquisitions

### **Acquisition of Tower Semiconductor**

During the first quarter of 2022, we entered into a definitive agreement to acquire Tower Semiconductor Ltd. (Tower) in a cash-for-stock transaction. Tower is a leading foundry for analog semiconductor solutions. The acquisition is expected to advance our IDM 2.0 strategy by accelerating our global end-to-end foundry business. Upon completion of the acquisition, each issued and outstanding ordinary share of Tower will be converted into the right to receive \$53 per share in cash, representing a total enterprise value of approximately \$5.4 billion as of the agreement date. We continue to work to close the transaction, which is subject to certain regulatory approvals and customary closing conditions. If regulatory approvals are not received prior to August 15, 2023, and the agreement is terminated by either party, we may be obligated to pay Tower a termination fee of \$353 million. Tower will be included in our IFS operating segment.

#### **Divestitures**

## **NAND Memory Business**

On December 29, 2021, we closed the first phase of our agreement with SK hynix Inc. (SK hynix) to divest our NAND memory business for \$9.0 billion in cash. Our NAND memory business includes our NAND memory technology and manufacturing business (the NAND OpCo Business), of which we deconsolidated our ongoing interests in as part of the sale. The transaction will be completed in two closings and upon first closing in the first three months 2022, SK hynix paid \$7.0 billion of consideration and we recognized a pre-tax gain of \$1.0 billion within *interest and other, net*, and tax expense of \$495 million. We recorded a receivable in *other long-term assets* for the remaining proceeds of \$1.9 billion which remains outstanding as of April 1, 2023, and will be received upon the second closing of the transaction, expected to be no earlier than March 2025.

The wafer manufacturing and sale agreement includes incentives and penalties that are contingent on the cost of operation and output of the NAND OpCo Business. These incentives and penalties present a maximum exposure of up to \$500 million annually, and \$1.5 billion in the aggregate. We are currently in negotiations with SK hynix to update the operating plan of the NAND OpCo Business in light of the current business environment and projections, which may impact the metrics associated with the incentives and penalties and our expectations of the performance of the NAND OpCo Business against those metrics.

As of April 1, 2023, we also have a receivable due from the NAND OpCo Business, a deconsolidated entity, of \$184 million recorded within *other current assets* on the Consolidated Condensed Balance Sheets. We will be reimbursed for costs of approximately \$35 million per quarter in 2023 for corporate function services, which include human resources, information technology, finance, supply chain, and other compliance requirements associated with being wholly owned subsidiaries.

## Note 9: Borrowings

In the first quarter of 2023, we issued a total of \$11.0 billion aggregate principal amount of senior notes. We also amended both our 5-year \$5.0 billion revolving credit facility agreement, extending the maturity date by one year to March 2028, and our 364-day credit facility agreement, extending the maturity date to March 2024. The revolving credit facilities had no borrowings outstanding as of April 1, 2023.

We have an ongoing authorization from our Board of Directors to borrow up to \$10.0 billion under our commercial paper program. In the first quarter of 2023, we settled in cash \$2.9 billion of our commercial paper and had \$1.0 billion outstanding as of April 1, 2023.

Our senior fixed rate notes pay interest semiannually. We may redeem the fixed rate notes prior to their maturity at our option at specified redemption prices and subject to certain restrictions. The obligations under our senior fixed rate notes rank equally in the right of payment with all of our other existing and future senior unsecured indebtedness and effectively rank junior to all liabilities of our subsidiaries.

## Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis

				Apr 1	, 202	3						Dec 31	l, 20	22		
	Fair Value Measured and Recorded at Reporting Date Using							Fair Value Measured and Recorded at Reporting Date Using								
(In Millions)	Leve	el 1	Lev	vel 2	Lev	rel 3		otal	Le	vel 1	Le	vel 2	Lev	el 3		otal
Assets																
Cash equivalents:																
Corporate debt	\$	_	\$ 1	,395	\$	_	\$ 1	1,395	\$	_	\$	856	\$	_	\$	856
Financial institution instruments <sup>1</sup>	1,8	306	2	,177		_	3	3,983	6	3,899		1,474		_	8	3,373
Government debt <sup>2</sup>	2	233		297				530		_		_				
Reverse repurchase agreements		_	1	,700			•	1,700		_		1,301		_	1	1,301
Short-term investments:																
Corporate debt		_	5	,441			5	5,441		_	į	5,381		_	5	5,381
Financial institution instruments <sup>1</sup>	1	141	5	,019			5	5,160		196	4	1,729		_	4	1,925
Government debt <sup>2</sup>		49	8	,652			8	3,701		48	6	5,840		_	6	5,888
Other current assets:																
Derivative assets		78		959		_		1,037		_		1,264		_	1	1,264
Loans receivable <sup>3</sup>		_		54		_		54		_		53		_		53
Marketable equity securities	1,4	121		_		_		1,421	1	,341		_		_	1	1,341
Other long-term assets:																
Derivative assets		_		5		_		5		_		10		_		10
Total assets measured and recorded at fair value	\$ 3,7	728	\$25	5,699	\$		\$2	9,427	\$ 8	3,484	\$2	1,908	\$	_	\$3	0,392
Liabilities																
Other accrued liabilities:																
Derivative liabilities	\$	8	\$	350	\$	81	\$	439	\$	111	\$	485	\$	89	\$	685
Other long-term liabilities:																
Derivative liabilities		_		515		_		515		_		699		_		699
Total liabilities measured and recorded at fair value	\$	8	\$	865	\$	81	\$	954	\$	111	\$ '	1,184	\$	89	\$ 1	1,384
1							_									

Level 1 investments consist of money market funds. Level 2 investments consist primarily of commercial paper, certificates of deposit, time deposits, and notes and bonds issued by financial institutions.

## Assets Measured and Recorded at Fair Value on a Non-Recurring Basis

Our non-marketable equity securities, equity method investments, and certain non-financial assets, such as intangible assets and property, plant and equipment, are recorded at fair value only if an impairment or observable price adjustment is recognized in the current period. If an observable price adjustment or impairment is recognized on our non-marketable equity securities during the period, we classify these assets as Level 3.

## Financial Instruments Not Recorded at Fair Value on a Recurring Basis

Financial instruments not recorded at fair value on a recurring basis include non-marketable equity securities and equity method investments that have not been remeasured or impaired in the current period, grants receivable, reverse repurchase agreements with original maturities greater than three months, and issued debt.

<sup>&</sup>lt;sup>2</sup> Level 1 investments consist primarily of US Treasury securities. Level 2 investments consist primarily of non-US government debt.

<sup>&</sup>lt;sup>3</sup> The fair value of our loans receivable for which we elected the fair value option did not significantly differ from the contractual principal balance.

We classify the fair value of grants receivable and reverse repurchase agreements with original maturities greater than three months as Level 2. The estimated fair value of these financial instruments approximates their carrying value. The aggregate carrying value of grants receivable as of April 1, 2023 was \$459 million (the aggregate carrying value as of December 31, 2022 was \$437 million). The aggregate carrying value of reverse repurchase agreements with original maturities greater than three months as of April 1, 2023 was \$0 million (the aggregate carrying value as of December 31, 2022 was \$400 million).

We classify the fair value of issued debt (excluding any commercial paper) as Level 2. The fair value of our issued debt was \$45.9 billion as of April 1, 2023 (\$34.3 billion as of December 31, 2022).

## Note 11: Derivative Financial Instruments

## Volume of Derivative Activity

Total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows:

(In Millions)	Apr 1, 2023		Dec	31, 2022
Foreign currency contracts	\$	30,847	\$	31,603
Interest rate contracts		16,590		16,011
Other		2,058		2,094
Total	\$	49,495	\$	49,708

## Fair Value of Derivative Instruments in the Consolidated Condensed Balance Sheets

		Apr 1	, 2023	Dec 31, 2022				
(In Millions)		Assets <sup>1</sup>		Liabilities <sup>2</sup>		Assets <sup>1</sup>		bilities <sup>2</sup>
Derivatives designated as hedging instruments:								
Foreign currency contracts <sup>3</sup>	\$	187	\$	185	\$	142	\$	290
Interest rate contracts		_		585		_		777
Total derivatives designated as hedging instruments		187		770		142		1,067
Derivatives not designated as hedging instruments:								
Foreign currency contracts <sup>3</sup>		537		156		866		194
Interest rate contracts		240		20		266		12
Equity contracts		78		8		_		111
Total derivatives not designated as hedging instruments		855		184		1,132		317
Total derivatives	\$	1,042	\$	954	\$	1,274	\$	1,384

<sup>&</sup>lt;sup>1</sup> Derivative assets are recorded as other assets, current and long-term.

<sup>&</sup>lt;sup>2</sup> Derivative liabilities are recorded as other liabilities, current and long-term.

The substantial majority of these instruments mature within 12 months.

## Amounts Offset in the Consolidated Condensed Balance Sheets

Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows:

	Apr 1, 2023											
								ss Amour the Bala				
(In Millions)		Gross nounts ognized	Amo Offse Bal	oss ounts t in the ance neet	Pre the	Net mounts sented in Balance Sheet		ancial uments	No Co Rec	sh and on-Cash ollateral ceived or ledged	Net Am	ount
Assets:												
Derivative assets subject to master netting arrangements	\$	966	\$	_	\$	966	\$	(471)	\$	(495)	\$	_
Reverse repurchase agreements		1,700				1,700				(1,700)		
Total assets		2,666				2,666		(471)		(2,195)		
Liabilities:  Derivative liabilities subject to master netting arrangements		935				935		(471)		(392)		72
Total liabilities	\$	935	\$		\$	935	\$	(471)	\$	(392)	\$	72
Total habilities			<u> </u>		_			(47.1)		(002)		
	Dec 31, 2022											
								ss Amourn the Bala				
(In Millions)	An	iross nounts ognized	Amo Offse Bal	oss ounts t in the ance neet	Pre the	Net mounts sented in Balance Sheet	Fin	ancial	Cash and Non-Cash Collateral Received or		Net Am	ount
Assets:	Nec	ognizeu	31	ieet		Sileet	IIISU	unients		ledged	Net All	Ount
Derivative assets subject to master netting arrangements  Reverse repurchase agreements	\$	1,231 1,701	\$	_	\$	1,231 1,701	\$	(546)	\$	(682) (1,701)	\$	3
Total assets		2,932				2,932		(546)		(2,383)		
Liabilities:		2,932			_	2,332		(340)	_	(2,303)		
Derivative liabilities subject to master netting arrangements		1,337		_		1,337		(546)		(712)		79
- 4 1 11 1 1114												
Total liabilities	\$	1,337	\$		\$	1,337	\$	(546)	\$	(712)	\$	79

We obtain and secure available collateral from counterparties against obligations, including securities lending transactions and reverse repurchase agreements, when we deem it appropriate.

## Derivatives in Cash Flow Hedging Relationships

The before-tax net gains or losses attributed to cash flow hedges recognized in *other comprehensive income (loss)* were \$53 million net gains in the first three months of 2023 (\$115 million net losses in the first three months of 2022). Substantially all of our cash flow hedges were foreign currency contracts for all periods presented.

During the first three months of 2023 and 2022, the amounts excluded from effectiveness testing were insignificant.

## Derivatives in Fair Value Hedging Relationships

The effects of derivative instruments designated as fair value hedges, recognized in *interest and other, net* for each period were as follows:

	Co	s (Losses) nsolidated atements d Deriv	d Cond	ensed
		Three Mor	ths En	ded
(In Millions)	Apr	1, 2023	Apr	2, 2022
Interest rate contracts	\$	192	\$	(711)
Hedged items		(192)		711
Total	\$	_	\$	_

The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows:

Line Item in the Consolidated Condensed Balance Sheets in Which the Hedged Item is Included	Hedged	Amount of the Item Asset/ ibilities)	Value Hedgir Included in	amount of Fair ng Adjustment the Carrying ets/(Liabilities)
(In Millions)	Apr 1, 2023	Dec 31, 2022	Apr 1, 2023	Dec 31, 2022
Long-term debt	\$ (11,41	3) \$ (11,221)	\$ 584	\$ 776

The total notional amount of pay-variable and receive-fixed interest rate swaps was \$12.0 billion as of April 1, 2023 and \$12.0 billion as of December 31, 2022.

## Derivatives Not Designated as Hedging Instruments

The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Income for each period were as follows:

		Three Months Ended					
(In Millions)	Location of Gains (Losses)  Recognized in Income on Derivatives	Apr	1, 2023	Apr 2, 2022			
Foreign currency contracts	Interest and other, net	\$	1	\$	158		
Interest rate contracts	Interest and other, net		(34)		94		
Other	Various		115		(134)		
Total		\$	82	\$	118		

# Note 12 : Contingencies

### Legal Proceedings

We are regularly party to various ongoing claims, litigation, and other proceedings, including those noted in this section. We have accrued a charge of \$2.2 billion related to litigation involving VLSI, described below. Excluding the VLSI claims described below, management at present believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, results of operations, cash flows, or overall trends; however, legal proceedings and related government investigations are subject to inherent uncertainties, and unfavorable rulings, excessive verdicts, or other events could occur. Unfavorable resolutions could include substantial monetary damages, fines, or penalties. Certain of these outstanding matters include speculative, substantial, or indeterminate monetary awards. In addition, in matters for which injunctive relief or other conduct remedies are sought, unfavorable resolutions could include an injunction or other order prohibiting us from selling one or more products at all or in particular ways, precluding particular business practices, or requiring other remedies. An unfavorable outcome may result in a material adverse impact on our business, results of operations, financial position, and overall trends. We might also conclude that settling one or more such matters is in the best interests of our stockholders, employees, and customers, and any such settlement could include substantial payments. Except as specifically described below, we have not concluded that settlement of any of the legal proceedings noted in this section is appropriate at this time.

#### **European Commission Competition Matter**

In 2009, the European Commission (EC) found that Intel had used unfair business practices to persuade customers to buy microprocessors in violation of Article 82 of the EC Treaty (later renumbered Article 102) and Article 54 of the European Economic Area Agreement. In general, the EC found that we violated Article 82 by offering alleged "conditional rebates and payments" that required customers to purchase all or most of their x86 microprocessors from us and by making alleged "payments to prevent sales of specific rival products." The EC ordered us to end the alleged infringement referred to in its decision and imposed a €1.1 billion fine, which we paid in the third quarter of 2009.

We appealed the EC decision to the European Court of Justice in 2014, after the General Court (then called the Court of First Instance) rejected our appeal of the EC decision in its entirety. In September 2017, the Court of Justice sent the case back to the General Court to examine whether the rebates at issue were capable of restricting competition.

In January 2022, the General Court annulled the EC's 2009 findings against Intel regarding rebates, as well as the fine imposed on Intel, which was returned to us in February 2022. In April 2022, the EC appealed the General Court's decision to the Court of Justice. A hearing date on the appeal has not been scheduled. The General Court's January 2022 decision did not annul the EC's 2009 finding that Intel made payments to prevent sales of specific rival products, and in January 2023 the EC reopened its administrative procedure to determine a fine against Intel based on that alleged conduct. Given the procedural posture and the nature of this proceeding, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from this matter.

In a related matter, in April 2022 we filed applications with the General Court seeking an order requiring the EC to pay Intel approximately €593 million in default interest, which applications have been stayed pending the EC's appeal of the General Court's January 2022 decision.

#### Litigation Related to Security Vulnerabilities

In June 2017, a Google research team notified Intel and other companies that it had identified security vulnerabilities, now commonly referred to as "Spectre" and "Meltdown," that affect many types of microprocessors, including our products. As is standard when findings like these are presented, we worked together with other companies in the industry to verify the research and develop and validate software and firmware updates for impacted technologies. In January 2018, information on the security vulnerabilities was publicly reported before software and firmware updates to address the vulnerabilities were made widely available.

Numerous lawsuits have been filed against Intel relating to Spectre, Meltdown, and other variants of the security vulnerabilities that have been identified since 2018. As of January 25, 2023, consumer class action lawsuits against Intel were pending in the United States, Canada, and Argentina. The plaintiffs, who purport to represent various classes of purchasers of our products, generally claim to have been harmed by Intel's actions and/or omissions in connection with the security vulnerabilities and assert a variety of common law and statutory claims seeking monetary damages and equitable relief. In the United States, class action suits filed in various jurisdictions were consolidated for all pretrial proceedings in the US District Court for the District of Oregon, which entered final judgment in favor of Intel in July 2022 based on plaintiffs' failure to plead a viable claim. Plaintiffs have appealed that decision to the Ninth Circuit Court of Appeals. In Canada, an initial status conference has not yet been scheduled in one case pending in the Superior Court of Justice of Ouebec is in effect. In Argentina, Intel Argentina was served with, and responded to, a class action complaint in June 2022. Additional lawsuits and claims may be asserted seeking monetary damages or other related relief. We dispute the pending claims described above and intend to defend those lawsuits vigorously. Given the procedural posture and the nature of those cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class or classes being certified or the ultimate size of any class or classes if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from those matters.

### Litigation Related to 7nm Product Delay Announcement

Multiple securities class action lawsuits were filed in the US District Court for the Northern District of California against Intel and certain officers following Intel's July 2020 announcement of 7nm product delays. The court consolidated the lawsuits and appointed lead plaintiffs in October 2020, and in January 2021 plaintiffs filed a consolidated complaint. Plaintiffs purport to represent all persons who purchased or otherwise acquired Intel common stock from October 25, 2019 through October 23, 2020, and they generally allege that defendants violated the federal securities laws by making false or misleading statements about the timeline for 7nm products. In March 2023, the court granted defendants' motion to dismiss the consolidated complaint, with leave to amend. Given the procedural posture and the nature of the case, including that it is in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class being certified or the ultimate size of any class if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from the matter. In July 2021, Intel introduced a new process node naming structure, and the 7nm process is now called Intel 4.

## Litigation Related to Patent and IP Claims

We have had IP infringement lawsuits filed against us, including but not limited to those discussed below. Most involve claims that certain of our products, services, and technologies infringe others' IP rights. Adverse results in these lawsuits may include awards of substantial fines and penalties, costly royalty or licensing agreements, or orders preventing us from offering certain features, functionalities, products, or services. As a result, we may have to change our business practices, and develop non-infringing products or technologies, which could result in a loss of revenue for us and otherwise harm our business. In addition, certain agreements with our customers require us to indemnify them against certain IP infringement claims, which can increase our costs as a result of defending such claims, and may require that we pay significant damages, accept product returns, or supply our customers with non-infringing products if there were an adverse ruling in any such claims. In addition, our customers and partners may discontinue the use of our products, services, and technologies, as a result of injunctions or otherwise, which could result in loss of revenue and adversely affect our business.

### VLSI Technology LLC v. Intel

In October 2017, VLSI Technology LLC (VLSI) filed a complaint against Intel in the US District Court for the Northern District of California alleging that various Intel FPGA and processor products infringe eight patents that VLSI acquired from NXP Semiconductors, N.V. (NXP). Four patents remain at issue in the case, and VLSI estimates its damages to be approximately \$900 million, and seeks enhanced damages, future royalties, attorneys' fees, costs, and interest. Intel filed Inter Partes Review (IPR) petitions with the Patent Trial and Appeal Board (PTAB) in 2018 challenging patentability, and the parties stipulated to stay the district court action pending the PTAB's review. The PTAB subsequently found all claims of two patents, and some claims of two other patents, to be unpatentable. The district court lifted the stay in September 2021 and scheduled trial for March 2024 on the claims that were found patentable by the PTAB.

In June 2018, VLSI filed a second suit against Intel, in US District Court for the District of Delaware, seeking \$4.4 billion in damages for the alleged infringement by various Intel processors of five additional patents that VLSI acquired from NXP. In December 2022, VLSI stipulated to dismiss with prejudice its claims, for which Intel paid nothing. The court dismissed the case in January 2023.

In April 2019, VLSI filed three infringement suits against Intel in the US District Court for the Western District of Texas accusing various Intel processors of infringement of eight additional patents it had acquired from NXP. The first Texas case went to trial in February 2021, and the jury awarded VLSI \$1.5 billion for literal infringement of one patent and \$675 million for infringement of another patent under the doctrine of equivalents. In April 2022, the court entered final judgment, awarding VLSI \$2.2 billion in damages and approximately \$162.3 million in pre-judgment and post-judgment interest. Intel has appealed the judgment to the Federal Circuit Court of Appeals, including its claim to have a license from Fortress Investment Group's acquisition of Finjan. In December 2021 and January 2022, the PTAB instituted IPRs on the claims found to have been infringed in the first Texas case, but it has not yet issued a final written decision on either petition.

The second Texas case went to trial in April 2021, and the jury found that Intel does not infringe the asserted patents. VLSI had sought approximately \$3.0 billion for alleged infringement, plus enhanced damages for willful infringement. The court has not yet entered final judgment following the second trial in Texas. The third Texas case went to trial in November 2022, with VLSI asserting one remaining patent. The jury found the patent valid and infringed, and awarded VLSI approximately \$949 million in damages, plus a running royalty. The court has not yet entered final judgment following the third trial in Texas. In February 2023, Intel filed motions for a new trial and for judgment as a matter of law notwithstanding the verdict on various grounds. Further appeals are possible.

In May 2019, VLSI filed a case in Shenzhen Intermediate People's Court against Intel, Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. VLSI asserts one patent against certain Intel Core processors. Defendants filed an invalidation petition in October 2019 with the China National Intellectual Property Administration (CNIPA), which held a hearing in September 2021. CNIPA has not yet issued a decision. The Shenzhen court held trial proceedings in July 2021 and stated that further trial proceedings were needed but would be stayed pending the outcome of defendants' invalidity challenge at the CNIPA. VLSI seeks an injunction as well as RMB 1.3 million in costs and expenses, but no damages.

In May 2019, VLSI filed a case in Shanghai Intellectual Property Court against Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. asserting one patent against certain Intel core processors. The court held a trial hearing in December 2020, where VLSI requested expenses (RMB 300 thousand) and an injunction. The court held a second trial hearing in May 2022, but has yet to issue its final decision. In December 2022, Intel filed a second petition to invalidate the patent at issue.

Intel has accrued a charge of approximately \$2.2 billion related to the VLSI litigation. While we dispute VLSI's claims and intend to vigorously defend against them, we are unable to make a reasonable estimate of losses in excess of recorded amounts given recent developments and future proceedings.

# **Key Terms**

**US GAAP** 

VIE

**VLSI** 

vRAN

intel

We use terms throughout our document that are specific to Intel or that are abbreviations that may not be commonly known or used. Below is a list of these terms used in our document.

Term	Definition
5G	The fifth-generation mobile network, which brings dramatic improvements in network speeds and latency, and which we view as a transformative technology and opportunity for many industries
ADAS	Advanced driver-assistance systems
ASP	Average selling price
AXG	Advanced Computing and Graphics operating segment
CCG	Client Computing Group operating segment
CODM	Chief operating decision maker
CPU	Processor or central processing unit
DCAI	Data Center and Artificial Intelligence operating segment
EC	European Commission
EPS	Earnings per share
Form 10-K	Annual Report on Form 10-K for the year ended December 31, 2022
Form 10-Q	Quarterly Report on Form 10-Q for the quarter ended April 1, 2023
FPGA	Field-programmable gate array
GPU	Graphics processing unit
IDM	Integrated device manufacturer, a semiconductor company that both designs and builds chips
IFS	Intel Foundry Services operating segment
IP	Intellectual property
IPO	Initial public offering
MD&A	Management's Discussion and Analysis
MG&A	Marketing, general, and administrative
MNC	Multinational corporation
NAND	NAND flash memory
Network Xeon	Part of the Intel Xeon processor family designed for network and edge solutions
NEX	Networking and Edge operating segment
nm	Nanometer
ODM	Original design manufacturer
R&D	Research and development
RSU	Restricted stock unit
SEC	US Securities and Exchange Commission
SoC	A system on a chip, which integrates most of the components of a computer or other electronic system into a single silicon chip. We offer a range of SoC products in CCG, DCAI, and NEX. In our DCAI and NEX businesses, we offer SoCs across many market segments for a variety of applications, including products targeted for 5G base stations and network infrastructure
SSD	Solid-state drive
US	United States

Virtualized radio access network

Variable interest entity

VLSI Technology LLC

US Generally Accepted Accounting Principles

# Management's Discussion and Analysis

This report should be read in conjunction with the Consolidated Financial Statements in our Form 10-K where we include additional information on our business, operating segments, risk factors, critical accounting estimates, policies, and the methods and assumptions used in our estimates, among other important information.

We previously announced the organizational change to integrate AXG into CCG and DCAI to drive a more effective go-to-market capability, accelerating the scale of these businesses while further reducing costs. As a result, we modified our segment reporting in the first quarter of 2023 to align to this and certain other business reorganizations. All prior-period segment data has been retrospectively adjusted to reflect the way we internally manage and monitor segment performance starting in fiscal year 2023.

"Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements of this Form 10-Q reconciles our segment revenues presented below to our total revenues, and our segment operating margin (loss) presented below to our total operating margin (loss), for each of the periods presented.

For additional key highlights of our results of operations, see "A Quarter in Review."

## **Client Computing**

We are committed to advancing PC experiences by delivering an annual cadence of leadership products and deepening our relationships with industry partners to co-engineer and deliver leading platform innovation. We engage in an intentional effort focused on a long-term operating system, system architecture, hardware, and application integration that enables industry-leading PC experiences. We will embrace these opportunities by simplifying and focusing our roadmap, ramping PC capabilities even more aggressively, and designing PC experiences even more deliberately. By doing this, we believe we will continue to fuel innovation across Intel, providing a growing source of IP, scale, and cash flow.



# Q1 2023 vs. Q1 2022

- Notebook revenue was \$3.4 billion, down \$2.6 billion from Q1 2022. Notebook volume decreased 37% in Q1 2023 due to customers tempering purchases to reduce existing inventories and due to lower demand. Notebook ASPs decreased 9% in Q1 2023 due to a higher mix of small core and older generation products.
- Desktop revenue was \$1.9 billion, down \$762 million from Q1 2022. Desktop volume decreased 32% in Q1 2023, driven by lower demand in the small and medium business and education market segments, and due to customers tempering purchases to reduce existing inventories. Desktop ASPs increased 5% in Q1 2023 due to an increased mix of commercial and gaming products.
- Other revenue was \$481 million, down \$241 million from Q1 2022, primarily driven by lower demand for our wireless and connectivity products.

## **Operating Income Summary**


Operating income decreased 81% from Q1 2022, with an operating margin of 9%.

## (In Millions)

•	,	
\$	520	Q1 2023 CCG Operating Income
	(2,358)	Lower product margin primarily from notebook and desktop revenue
	(164)	Higher desktop unit cost primarily from increased mix of Intel 7 products
	(120)	Higher period charges related to excess capacity charges
	251	Lower period charges primarily driven by a decrease in product ramp costs
	200	Lower operating expenses driven by various cost-cutting measures
	(11)	Other
\$	2,722	Q1 2022 CCG Operating Income

## Data Center and Al

DCAI delivers industry-leading workload-optimized solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. We are uniquely positioned to deliver solutions to help solve our customers' most complex challenges with the depth and breadth of our hardware and software portfolio combined with silicon and platforms, advanced packaging, and at-scale manufacturing made possible by being the world's only IDM at scale. Our customers and partners include cloud hyperscalers, MNCs, small and medium-sized businesses, independent software vendors, systems integrators, communications service providers, and governments around the world.



# Q1 2023 vs. Q1 2022

Revenue was \$3.7 billion, down \$2.4 billion from Q1 2022, driven by a decrease in server revenue. Server volume decreased 50% in Q1 2023, due to lower demand and from customers tempering purchases to reduce existing inventories in a softening data center market. The decrease in server revenue was partially offset by an increase in revenue from the FPGA product line.


### Operating Income (Loss) Summary

We had an operating loss of \$518 million, compared to operating income of \$1.4 billion in Q1 2022.

(In M	lillions)	
\$	(518)	Q1 2023 DCAI Operating Income (Loss)
	(1,935)	Lower server product margin due to lower server revenue, partially offset by an increase in product margin from higher DCAI other product revenue
	(257)	Higher server unit cost from increased mix of 10nm SuperFin products
	(154)	Higher period charges related to excess capacity charges
	199	Lower operating expenses driven by various cost-cutting measures
	193	Lower period charges primarily driven by a decrease in product ramp costs
	135	Lower period charges driven by the sell-through of previously reserved inventory
	(92)	Other
\$	1,393	Q1 2022 DCAI Operating Income (Loss)

## Network & Edge

NEX lifts the world's networks and edge compute systems from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. We work with partners and customers to deliver and deploy intelligent edge platforms that allow software developers to achieve agility and to drive automation using AI for efficient operations while securing the integrity of their data at the edge. We have a broad portfolio of hardware and software platforms, tools, and ecosystem partnerships for the rapid digital transformation happening from the cloud to the edge. We are leveraging our core strengths in process, software, and manufacturing at scale to grow traditional markets and to accelerate entry into emerging ones.



#### Q1 2023 vs. Q1 2022

Revenue was \$1.5 billion, down \$650 million from Q1 2022, as customers tempered purchases to reduce existing inventories and adjust to a lower demand environment for Edge, Network Xeon and Ethernet products.

### Operating Income (Loss) Summary


We had an operating loss of \$300 million, compared to operating income of \$416 million in Q1 2022.

/1	Millions)	

(	,	
\$	(300)	Q1 2023 NEX Operating Income (Loss)
	(475)	Lower product margin from lower Edge, Network Xeon, and Ethernet revenue
	(139)	Higher period charges driven by inventory reserves taken in Q1 2023
	(102)	Other, including lower operating expenses driven by various cost-cutting measures
\$	416	Q1 2022 NEX Operating Income (Loss)

## Mobileye

Mobileye is a global leader in driving assistance and self-driving solutions. Our product portfolio is designed to encompass the entire stack required for assisted and autonomous driving, including compute platforms, computer vision, and machine learning-based perception, mapping and localization, driving policy, and active sensors in development. We pioneered ADAS technology more than 20 years ago, and have continuously expanded the scope of our ADAS offerings while leading the evolution to autonomous driving solutions. Our unique assets in ADAS allow for building a scalable self-driving stack that meets the requirements for both robotaxi and consumer-owned autonomous vehicles. Our customers and strategic partners include major global original equipment manufacturers, Tier 1 automotive system integrators, and public transportation operators.




### Revenue and Operating Income Summary

### Q1 2023 vs. Q1 2022

Revenue was \$458 million, up \$64 million from Q1 2022 primarily driven by higher demand for EyeQ® products and Mobileye SuperVision\* systems. Operating income was \$123 million, down \$25 million from Q1 2022, primarily due to increased investments in leadership products.

## Intel Foundry Services

As the first Open System Foundry, we offer customers differentiated full stack solutions created from the best of Intel and the foundry industry ecosystem, delivered from a secure and sustainable source of supply with an array of flexible business models to enable customers to lead in their industry. In addition to a world-class foundry offering enabled by a rich ecosystem, customers have access to our expertise and technologies, including cores, accelerators, and advanced packaging such as Embedded Multi-die Interconnect Bridge. Our early customers and strategic partners include traditional fabless customers, cloud service providers, automotive customers, and military, aerospace, and defense firms. We also offer mask-making equipment for advanced lithography used by many of the world's leading-edge foundries.



### Revenue and Operating Income (Loss) Summary


#### Q1 2023 vs. Q1 2022

Revenue was \$118 million, down \$38 million from Q1 2022 driven by lower sales of multi-beam mask writer tools. We had an operating loss of \$140 million, compared to an operating loss of \$23 million in Q1 2022, primarily due to increased factory startup costs.

# Consolidated Condensed Results of Operations

Three Months Ended							
	Q1 2023				Q1 2022		
(In Millions, Except Per Share Amounts)		Amount	% of Net Revenue		Amount	% of Net Revenue	
Net revenue	\$	11,715	100.0 %	\$	18,353	100.0 %	
Cost of sales		7,707	65.8 %		9,109	49.6 %	
Gross margin		4,008	34.2 %		9,244	50.4 %	
Research and development		4,109	35.1 %		4,362	23.8 %	
Marketing, general, and administrative		1,303	11.1 %		1,752	9.5 %	
Restructuring and other charges		64	0.5 %		(1,211)	(6.6)%	
Operating income (loss)		(1,468)	(12.5)%		4,341	23.7 %	
Gains (losses) on equity investments, net		169	1.4 %		4,323	23.6 %	
Interest and other, net		141	1.2 %		997	5.4 %	
Income (loss) before taxes		(1,158)	(9.9)%		9,661	52.6 %	
Provision for taxes		1,610	13.7 %		1,548	8.4 %	
Net income (loss)		(2,768)	(23.6)%		8,113	44.2 %	
Less: Net income (loss) attributable to non-controlling interests		(10)	(0.1)%		_	— %	
Net income (loss) attributable to Intel	\$	(2,758)	(23.5)%	\$	8,113	44.2 %	
Earnings (loss) per share attributable to Intel—diluted	\$	(0.66)		\$	1.98		

### Segment Revenue Walk \$B



Q1 2023 results were impacted by an uncertain macroeconomic environment, with slowing consumer and enterprise demand, persistent inflation, and higher interest rates, that we believe impacts our target markets and creates a high level of uncertainty with our customers. We believe CCG, DCAI, and NEX customers, among others, tempered purchases to reduce their existing inventories and adjust to the macroeconomic uncertainty. We expect this macroeconomic uncertainty and the challenging market environment will continue during 2023.

#### Q1 2023 vs. Q1 2022

Our Q1 2023 revenue was \$11.7 billion, down \$6.6 billion or 36% from Q1 2022. CCG revenue decreased 38% from Q1 2022 due to lower notebook and desktop volumes on lower demand, while notebook ASPs decreased due to a higher mix of small core and older generation products. DCAI revenue decreased 39% from Q1 2022 due to lower server volume resulting from a softening data center market, partially offset by an increase in revenue from the FPGA product line. NEX revenue decreased 30% from Q1 2022, due to lower demand for Edge, Network Xeon, and Ethernet products.


Incentives offered to certain customers to compete in the market, accelerate purchases, and to strategically position our products with customers for market segment share purposes, particularly in CCG, contributed approximately \$900 million to our revenue during the first quarter of 2023, the impacts of which were contemplated in our financial guidance for Q2 2023 as included in our Form 8-K dated April 27, 2023.

# **Gross Margin**

We derived most of our overall gross margin in Q1 2023 from the sale of products in the CCG and DCAI operating segments. Our overall gross margin dollars in Q1 2023 decreased by \$5.2 billion, or 57% compared to Q1 2022.

## Gross Margin \$B

(Percentages in chart indicate gross margin as a percentage of total revenue)



## (In Millions)

,	
\$ 4,008	Q1 2023 Gross Margin
(2,358)	Lower product margin primarily from lower notebook and desktop revenue
(1,935)	Lower server product margin due to lower revenue, partially offset by an increase in product margin from higher DCAI other product revenue
(475)	Lower product margin from lower Edge, Network Xeon, and Ethernet revenue
(421)	Higher unit cost primarily from increased mix of Intel 7 and 10nm SuperFin products
(352)	Higher period charges related to excess capacity charges
444	Lower period charges primarily driven by a decrease in product ramp costs
(139)	Other
\$ 9,244	Q1 2022 Gross Margin

Effective January 2023, we increased the estimated useful life of certain production machinery and equipment from 5 years to 8 years. We estimate this change resulted in an approximate \$360 million increase to gross margin, an approximate \$100 million decrease in R&D expenses, and an approximate \$525 million decrease in ending inventory values in Q1 2023 when compared to what the impact would have been using the estimated useful life in place prior to this change.

When compared to the estimated useful life in place as of the end of 2022, we expect total depreciation expense in 2023 to be reduced by \$4.1 billion. We expect this change will result in an approximately \$2.3 billion increase to gross margin, a \$400 million decrease in R&D expenses, and a \$1.4 billion decrease in ending inventory values.


## **Operating Expenses**

Total R&D and MG&A expenses for Q1 2023 were \$5.4 billion, down 11% from Q1 2022. These expenses represent 46.2% of revenue for Q1 2023 and 33.3% of revenue for Q1 2022. In support of our strategy, described in our 2022 Form 10-K, we continue to make significant investments to accelerate our process technology roadmap. This requires continued investments in R&D and focused efforts to attract and retain talent. We have implemented certain cost-cutting measures while we continue to improve our product execution.

#### Research and Development \$B

Marketing, General, and Administrative \$B

(Percentages in chart indicate operating expenses as a percentage of total revenue)



#### Research and Development

#### Q1 2023 vs. Q1 2022

R&D decreased by \$253 million, or 6%, driven by the following:

- Lower incentive-based cash compensation
- + Increased investments in our process technology roadmap and additional corporate spending to drive strategic growth, partially offset by the effects of various cost-cutting measures

#### Marketing, General, and Administrative

### Q1 2023 vs. Q1 2022

MG&A decreased by \$449 million, or 26%, driven by the following:

- Lower corporate spending as a result of various cost-cutting measures
- Lower incentive-based cash compensation

## Restructuring and Other Charges

(In Millions)		21 2023	Q1 2022	
Employee severance and benefit arrangements	\$	(39)	\$	5
Litigation charges and other		77		(1,216)
Asset impairment charges		26		
Total restructuring and other charges	\$	64	\$	(1,211)

The 2022 Restructuring Program was approved in Q3 2022 to rebalance our workforce and operations to create efficiencies and improve our product execution in alignment with our strategy. During Q1 2023, activity related to the 2022 Restructuring Program substantially related to cash settlement of previously accrued employee severance and benefit arrangements and we expect any additional actions pursuant to the 2022 Restructuring Program to be substantially completed by the end of 2023, but this is subject to change. We expect that our 2022 Restructuring Plan, in conjunction with other initiatives, will reduce our cost structure and allow us to reinvest certain of these cost savings in resources and capacity to develop, manufacture, market, sell, and deliver our products in furtherance of our strategy.

Litigation charges and other includes a \$1.2 billion benefit in Q1 2022 from the annulled penalty related to an EC fine that was recorded and paid in 2009.

## Gains (Losses) on Equity Investments and Interest and Other, Net

(In Millions)	Q1	Q1 2022		
Ongoing mark-to-market adjustments on marketable equity securities	\$	188	\$	(430)
Observable price adjustments on non-marketable equity securities		10		71
Impairment charges		(36)		(23)
Sale of equity investments and other		7		4,705
Total gains (losses) on equity investments, net	\$	169	\$	4,323
Interest and other, net	\$	141	\$	997

## Gains (losses) on equity investments, net

Ongoing mark-to-market adjustments for Q1 2023 and Q1 2022 were primarily related to our interest in Montage Technology, Co. Ltd and others.

In Q1 2022, the sale of McAfee to an investor group was completed and we received \$4.6 billion in cash for the sale of our remaining share of McAfee, recognizing a \$4.6 billion gain in sale of equity investments and other.

#### Interest and other, net

In 2022, we recognized a gain of \$1.0 billion from the first closing of the divestiture of our NAND memory business.

## **Provision for Taxes**

(In Millions)		Q1 2023	Q1 2022		
Income (loss) before taxes	\$	(1,158)	\$	9,661	
Provision for taxes	\$	1,610	\$	1,548	
Effective tax rate		(139.0)%		16.0 %	

In Q1 2023, we recognized a provision for taxes as we applied our estimated annual effective tax rate to our year-to-date measure of ordinary income (loss) before taxes, which reflects a higher proportion of our income being taxed in non-US jurisdictions. Our effective tax rate decreased in Q1 2023 compared to Q1 2022, due to a loss before taxes, the application of our estimated annual effective tax rate, and the unfavorable tax rate effects associated with the gains recognized in Q1 2022 from the equity sale of McAfee and the divestiture of our NAND memory business.

## Liquidity and Capital Resources

We consider the following when assessing our liquidity and capital resources:

(In Millions)		r 1, 2023	Dec 31, 2022		
Cash and cash equivalents	\$	8,232	\$	11,144	
Short-term investments	19,302			17,194	
Loans receivable and other		64		463	
Total cash and investments <sup>1</sup> \$ 27,590		27,598	\$	28,801	
Total debt	\$ 50,273		\$	42,051	

We believe we have sufficient sources of funding to meet our business requirements for the next 12 months and in the longer term. Cash generated by operations, supplemented by our total cash and investments<sup>1</sup>, as shown in the preceding table, is our primary source of liquidity for funding our strategic business requirements. Our short-term funding requirements include capital expenditures for worldwide manufacturing and assembly and test, including investments in our process technology roadmap; working capital requirements; and potential and pending acquisitions, strategic investments, and dividends. This includes a commitment of \$5.4 billion associated with our pending acquisition of Tower. Our long-term funding requirements incrementally contemplate investments in significant manufacturing expansion plans and investments to accelerate our process technology.

Our *cash and investments* and related cash flows may be affected by certain discretionary actions we may take with customers and suppliers to accelerate or delay certain cash receipts or payments to manage liquidity for our strategic business requirements. These actions can include, among others, negotiating with suppliers to optimize our payment terms and conditions, adjusting the timing of cash flows associated with customer sales programs and collections, managing inventory levels and purchasing practices, and selling certain of our accounts receivables on a non-recourse basis to third party financial institutions.

We expect to benefit from government incentives, and any incentives above our current expectations would enable us to increase the pace and size of our IDM 2.0 investments. Conversely, incentives below our expectations would increase our anticipated cash requirements.

In Q1 2023, we declared a reduced quarterly dividend on our common stock. This dividend reduction reflects our deliberate approach to capital allocation, is expected to support the critical investments needed to execute our business strategy, and is designed to position us to create long-term value.

In Q1 2023, we issued a total of \$11.0 billion aggregate principal amount of senior notes. We intend to use the proceeds from the offering for general corporate purposes, including, but not limited to, refinancing of outstanding debt and funding for working capital and capital expenditures. We also amended both our 5-year \$5.0 billion revolving credit facility, extending the maturity date by one year to March 2028, and our 364-day \$5.0 billion credit facility agreement, extending the maturity date to March 2024. We have other potential sources of liquidity include our commercial paper program and our automatic shelf registration statement on file with the SEC, pursuant to which we may offer an unspecified amount of debt, equity, and other securities. Under our commercial paper program, we have an ongoing authorization from our Board of Directors to borrow up to \$10.0 billion and, as of April 1, 2023 we had \$1.0 billion of commercial paper obligations outstanding. As of April 1, 2023, we had no outstanding borrowings on the revolving credit facilities.

We maintain a diverse investment portfolio that we continually analyze based on issuer, industry, and country. Substantially all of our investments in debt instruments and financing receivables were in investment-grade securities.



<sup>&</sup>lt;sup>1</sup> See "Non-GAAP Financial Measures" within MD&A.

Thurs Mouths Fuded

	Inree Months Ended					
(In Millions)	Apr 1, 2023		Apr 2, 2022			
Net cash provided by (used for) operating activities	\$	(1,785)	\$	5,891		
Net cash used for investing activities		(8,521)		(2,639)		
Net cash provided by (used for) financing activities		7,394		(1,864)		
Net increase (decrease) in cash and cash equivalents	\$	(2,912)	\$	1,388		

#### **Operating Activities**

Operating cash flows consist of net income adjusted for certain non-cash items and changes in certain assets and liabilities.

The decrease in cash provided by operations in the first three months of 2023 was primarily driven by our net operating loss in comparison to our net operating income for the first three months of 2022.

#### **Investing Activities**

Investing cash flows consist primarily of capital expenditures; investment purchases, sales, maturities, and disposals; and proceeds from divestitures.

Cash used for investing activities was higher in the first three months of 2023 compared to the first three months of 2022, primarily due to the absence of proceeds from the divestiture of our NAND business and proceeds for our remaining share of McAfee, both of which occurred in the first three months of 2022; as well as higher capital expenditures in the first three months of 2023. These unfavorable cash impacts during the first three months of 2023 were partially offset by the favorable cash impacts of lower purchases of short-term investments, net of maturities and sales, during the first three months of 2023.

### **Financing Activities**

Financing cash flows consist primarily of payment of dividends to stockholders, issuance and repayment of short-term and long-term debt, and proceeds from the sale of shares of common stock through employee equity incentive plans.

Cash provided by financing activities in the first three months of 2023 compared to cash used for financing activities in the first three months of 2022 was primarily due to net proceeds from our debt issuance, partially offset by commercial paper repayments, during the first three months of 2023.

### Non-GAAP Financial Measures

In addition to disclosing financial results in accordance with US GAAP, this document contains references to the non-GAAP financial measures below. We believe these non-GAAP financial measures provide investors with useful supplemental information about our operating performance, enable comparison of financial trends and results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business and measuring our performance. These non-GAAP financial measures are used in our performance-based RSUs and our cash bonus plans.

Our non-GAAP financial measures reflect adjustments based on one or more of the following items, as well as the related income tax effects. Beginning in 2023, income tax effects are calculated using a fixed long-term projected tax rate across all adjustments. We project this long-term non-GAAP tax rate on an annual basis using a five-year non-GAAP financial projection that excludes the income tax effects of each adjustment. The projected non-GAAP tax rate also considers factors such as our tax structure, our tax positions in various jurisdictions, and key legislation in significant jurisdictions where we operate. This long-term non-GAAP tax rate may be subject to change for a variety of reasons, including the rapidly evolving global tax environment, significant changes in our geographic earnings mix, or changes to our strategy or business operations. Management uses this non-GAAP tax rate in managing internal short- and long-term operating plans and in evaluating our performance; we believe this approach facilitates comparison of our operating results and provides useful evaluation of our current operating performance. Prior-period non-GAAP results have been retroactively adjusted to reflect this updated approach.

These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with US GAAP, and the financial results calculated in accordance with US GAAP and reconciliations from these results should be carefully evaluated.

Non-GAAP adjustment or		
measure	Definition	Usefulness to management and investors
Acquisition-related adjustments	Amortization of acquisition-related intangible assets consists of amortization of intangible assets such as developed technology, brands, and customer relationships acquired in connection with business combinations. Charges related to the amortization of these intangibles are recorded within both cost of sales and MG&A in our US GAAP financial statements. Amortization charges are recorded over the estimated useful life of the related acquired intangible asset, and thus are generally recorded over multiple years.	We exclude amortization charges for our acquisition- related intangible assets for purposes of calculating certain non-GAAP measures because these charges are inconsistent in size and are significantly impacted by the timing and valuation of our acquisitions. These adjustments facilitate a useful evaluation of our current operating performance and comparison to our past operating performance and provide investors with additional means to evaluate cost and expense trends.
Share-based compensation	Share-based compensation consists of charges related to our employee equity incentive plans.	We exclude charges related to share-based compensation for purposes of calculating certain non-GAAP measures because we believe these adjustments provide better comparability to peer company results and because these charges are not viewed by management as part of our core operating performance. We believe these adjustments provide investors with a useful view, through the eyes of management, of our core business model, how management currently evaluates core operational performance, and additional means to evaluate expense trends, including in comparison to other peer companies.
Restructuring and other charges	Restructuring charges are costs associated with a formal restructuring plan and are primarily related to employee severance and benefit arrangements. Other charges may include periodic goodwill and asset impairments, certain pension charges, and costs associated with restructuring activity, and in Q1 2022 includes a benefit related to the annulled EC fine.	We exclude restructuring and other charges, including any adjustments to charges recorded in prior periods, for purposes of calculating certain non-GAAP measures because these costs do not reflect our core operating performance. These adjustments facilitate a useful evaluation of our core operating performance and comparisons to past operating results and provide investors with additional means to evaluate expense trends.
Gains (losses) from divestiture	Gains (losses) are recognized at the close of a divestiture, or over a specified deferral period when deferred consideration is received at the time of closing. Based on our ongoing obligation under the NAND wafer manufacturing and sale agreement entered into in connection with the first closing of the sale of our NAND memory business on December 29, 2021, a portion of the initial closing consideration was deferred and will be recognized between first and second closing.	We exclude gains or losses resulting from divestitures for purposes of calculating certain non-GAAP measures because they do not reflect our current operating performance. These adjustments facilitate a useful evaluation of our current operating performance and comparisons to past operating results.
(Gains) losses on equity investments, net	(Gains) losses on equity investments, net consists of ongoing mark-to-market adjustments on marketable equity securities, observable price adjustments on non-marketable equity securities, related impairment charges, and the sale of equity investments and other.	We exclude these non-operating gains and losses for purposes of calculating certain non-GAAP measures because it provides better comparability between periods. The exclusion reflects how management evaluates the core operations of the business.
Adjusted free cash flow	We reference a non-GAAP financial measure of adjusted free cash flow, which is used by management when assessing our sources of liquidity, capital resources, and quality of earnings. Adjusted free cash flow is operating cash flow adjusted for (1) additions to property, plant and equipment, net of proceeds from capital grants and partner contributions, (2) payments on finance leases, and (3) proceeds from the McAfee equity sale.	This non-GAAP financial measure is helpful in understanding our capital requirements and sources of liquidity by providing an additional means to evaluate the cash flow trends of our business. Since the 2017 divestiture, McAfee equity distributions and sales contributed to prior operating and free cash flow, and while the McAfee equity sale in Q1 2022 would have typically been excluded from adjusted free cash flow as an equity sale, we believe including the sale proceeds in adjusted free cash flow facilitate a better, more consistent comparison to past presentations of liquidity.
Total cash and investments	Total cash and investments is used by management when assessing our sources of liquidity, which include cash and cash equivalents, short-term investments, and loans receivable and other.	This non-GAAP measure is helpful in understanding our capital resources and liquidity position.

Following are the reconciliations of our most comparable US GAAP measures to our non-GAAP measures presented:

		Three Months Ended		
	Ar	or 1, 2023	Ар	r 2, 2022
Gross margin percentage		34.2 %		50.4 %
Acquisition-related adjustments		2.8 %		1.9 %
Share-based compensation		1.4 %		0.8 %
Non-GAAP gross margin percentage		38.4 %		53.1 %
Earnings (loss) per share attributable to Intel—diluted	\$	(0.66)	\$	1.98
Acquisition-related adjustments		0.09		0.10
Share-based compensation		0.18		0.17
Restructuring and other charges		0.01		(0.30)
(Gains) losses on equity investments, net		(0.04)		(1.05)
(Gains) losses from divestiture		(0.01)		(0.27)
Total adjustments attributable to non-controlling interest		_		_
Income tax effects		0.39		0.24
Non-GAAP earnings (loss) per share attributable to Intel—diluted	\$	(0.04)	\$	0.87
		Three Mon	ths E	inded
(In Millions)	Apr 1, 2023		Apr 2, 2022	
Net cash provided by (used for) operating activities	\$	(1,785)	\$	5,891
Net additions to property, plant and equipment		(6,964)		(4,603)
Payments on finance leases		(15)		(299)
Sale of equity investment		_		4,561
Adjusted free cash flow	\$	(8,764)	\$	5,550
Net cash used for investing activities	\$	(8,521)	\$	(2,639)
Net cash provided by (used for) financing activities	\$	7,394	\$	(1,864)

# Other Key Information

## Quantitative and Qualitative Disclosures About Market Risk

We are affected by changes in currency exchange and interest rates, as well as equity and commodity prices. Our risk management programs are designed to reduce, but may not entirely eliminate, the impacts of these risks. For a discussion about market risk and sensitivity analysis related to changes in currency exchange rates, interest rates, equity prices, and commodity prices refer to "Quantitative and Qualitative Disclosures About Market Risk" within MD&A in our 2022 Form 10-K.

## Risk Factors

The risks described in "Risk Factors" within Other Key Information in our 2022 Form 10-K could materially and adversely affect our business, financial condition, and results of operations, and the trading price of our common stock could decline. These risk factors do not identify all risks that we face—our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations. Due to risks and uncertainties, known and unknown, our past financial results may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods. Refer also to the other information set forth in this Form 10-Q, including in the Forward-Looking Statements, MD&A, and Consolidated Condensed Financial Statements and Supplemental Details sections.

## **Controls and Procedures**

#### Inherent Limitations on Effectiveness of Controls

Our management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.

#### **Evaluation of Disclosure Controls and Procedures**

Based on management's evaluation (with the participation of our principal executive officer and principal financial officer), as of the end of the period covered by this report, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)), were effective to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

## Changes in Internal Control Over Financial Reporting

There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended April 1, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Issuer Purchases of Equity Securities

We have an ongoing authorization, originally approved by our Board of Directors in 2005 and subsequently amended, to repurchase shares of our common stock in open market or negotiated transactions. No shares were repurchased during the quarter ending April 1, 2023. As of April 1, 2023, we were authorized to repurchase up to \$110.0 billion, of which \$7.2 billion remained available.

We issue RSUs as part of our equity incentive plans. In our Consolidated Condensed Financial Statements, we treat shares of common stock withheld for tax purposes on behalf of our employees in connection with the vesting of RSUs in a similar manner as common stock repurchases because they reduce the number of shares that would have been issued upon vesting. These withheld shares of common stock are not considered common stock repurchases under our authorized common stock repurchase program.

## Disclosure Pursuant to Section 13(r) of the Securities Exchange Act of 1934

Section 13(r) of the Exchange Act requires an issuer to disclose certain information in its periodic reports if it or any of its affiliates knowingly engaged in certain activities, transactions or dealings with individuals or entities subject to specific US economic sanctions during the reporting period, even when the activities, transactions, or dealings are conducted in compliance with applicable law. On March 2, 2021, the US Secretary of State designated the Federal Security Service of the Russian Federation (FSB) as a party subject to one such sanction. From time to time, our local subsidiaries are required to engage with the FSB as a licensing authority and file documents in order to conduct business within the Russian Federation. All such dealings are explicitly authorized by general licenses issued by the US Department of the Treasury's Office of Foreign Assets Control (OFAC), and there are no gross revenues or net profits directly associated with any such dealings by us with the FSB. As announced on April 5, 2022, Intel suspended all business operations in Russia until further notice, and we plan to continue limited activities as required to conduct business in the Russian Federation to the extent permitted by applicable law.

On April 15, 2021, the US Department of the Treasury designated Pozitiv Teknolodzhiz, AO (Positive Technologies), a Russian IT security firm, as a party subject to one of the sanctions specified in Section 13(r). Prior to the designation, we communicated with Positive Technologies regarding its IT security research and coordinated disclosure of security vulnerabilities identified by the firm. Based on a license issued by OFAC, we resumed such communications. There are no gross revenues or net profits directly associated with any such activities. We plan to continue these communications in accordance with the terms and conditions of the OFAC license.

## **Exhibits**

		Incorporated by Reference				
Exhibit Number	Exhibit Description	Form	File Number	Exhibit	Filing Date	Filed or Furnished Herewith
3.1	Third Restated Certificate of Incorporation of Intel Corporation, dated May 17, 2006	8-K	000-06217	3.1	5/22/2006	
3.2	Intel Corporation Bylaws, as amended and restated on March 10, 2021	8-K	000-06217	3.2	3/16/2021	
4.1	Nineteenth Supplemental Indenture, dated as of February 10, 2023, between Intel Corporation and Computershare Trust Company, National Association (as successor to Wells Fargo Bank, National Association), as trustee	8-K	000-06217	4.1	2/10/2023	
10.1†	Second Amendment to Intel Corporation Sheltered Employee Retirement Plan Plus dated January 1, 2023	10-K	000-6217	10.5	1/27/2023	
10.2†	Offer Letter between Intel Corporation and Christoph Schell dated February 11, 2022					X
31.1	Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act					X
31.2	Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act					X
32.1	Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350					Х
101	Inline XBRL Document Set for the consolidated condensed financial statements and accompanying notes in Consolidated Condensed Financial Statements and Supplemental Details					X
104	Cover Page Interactive Data File - formatted in Inline XBRL and included as Exhibit 101					Χ

<sup>&</sup>lt;sup>†</sup> Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.

# Form 10-Q Cross-Reference Index

Item Number	Item			
Part I - Financial Information				
Item 1.	Financial Statements	Pages <u>4</u> - <u>21</u>		
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations:			
	Liquidity and capital resources	Pages <u>33</u> - <u>34</u>		
	Results of operations	Pages <u>3,</u> <u>22</u> - <u>32</u>		
	Critical accounting estimates	Page <u>22</u>		
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	Page <u>37</u>		
Item 4.	Controls and Procedures	Page <u>37</u>		
Part II - Other Information				
Item 1.	Legal Proceedings	Pages <u>18</u> - <u>20</u>		
Item 1A.	Risk Factors	Page <u>37</u>		
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	Page <u>37</u>		
Item 3.	Defaults Upon Senior Securities	Not applicable		
Item 4.	Mine Safety Disclosures	Not applicable		
Item 5.	Other Information			
	Disclosure Pursuant to Section 13(r) of the Securities Exchange Act of 1934	Page <u>38</u>		
Item 6.	Exhibits	Page <u>39</u>		
Signatures		Page <u>41</u>		

## **Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

> INTEL CORPORATION (Registrant)

April 27, 2023 Date: By: /s/ DAVID ZINSNER

David Zinsner

Executive Vice President, Chief Financial Officer, and Principal Financial Officer

/s/ SCOTT GAWEL Date: April 27, 2023 By:

Scott Gawel

Corporate Vice President, Chief Accounting Officer, and

Principal Accounting Officer

intel